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RappORt IN Het kORt
Seksueel overdraagbare aandoeningen, waaronder HIV, in Nederland in 2007
Chlamydia, gonorroe, syfilis
Net als in 2006 was chlamydia in 2007 de meest gediagnosticeerde bacteriële geslachts-
ziekte in de soacentra, vooral bij jongeren. Het percentage positieve chlamydiatesten 
onder heteroseksuele mannen en vrouwen daalde enigszins, voor het eerst sinds vier jaar 
(van 10,6% naar 10,1%). In 2006 stabiliseerde dit percentage bij mannen die seks hebben 
met mannen (MSM), en die trend zette door in 2007. Het percentage positieve gonorroe-, 
syfilis- en hivtesten nam net als voorgaande jaren af in 2007 (respectievelijk 2,4%, 0,9% en 
0,5%). Deze infecties werden het meest gediagnosticeerd bij MSM. 
Hiv 
In 2007 zijn er 306 nieuwe hivdiagnoses gesteld in de soacentra, ongeveer een derde 
van de 864 hivpositieven die dat jaar landelijk in de hivcentra zijn gemeld. Eind 2007 
waren in totaal 14.019 personen in Nederland met hiv geregistreerd. Het aandeel van 
MSM onder de nieuw hivinfecties nam in 2007 verder toe. Net als eerdere jaren werd in 
de soacentra bij MSM die bekend zijn met hun positieve hivstatus vaak nog een andere 
geslachtsziekte gevonden (45%). In deze groep is sinds 2004 regelmatig LGV, een agres-
sieve variant van chlamydia, en sinds 2007 hepatitis C gediagnosticeerd. Versterkte 
surveillance en innovatieve interventies zijn nodig om verdere verspreiding onder MSM 
en naar andere groepen te voorkomen.
Migranten 
Onder bepaalde migrantengroepen in Nederland (onder andere afkomstig uit Suriname, 
de Nederlandse Antillen en Aruba) komen hiv, chlamydia, gonorroe en syfilis relatief vaker 
voor dan onder autochtone Nederlanders. Ook deze constatering vraagt om vernieuwende 
maatregelen die op de bevolkingsgroepen zijn toegespitst. 
De soacentra bieden soazorg aan hoogrisicogroepen. In 2007 hebben ruim 78.000 perso-
nen zich daar laten testen, een toename van 13% ten opzichte van 2006. 
trefwoorden: hiv/aids, soa, surveillance, trends, Nederland
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abStRaCt 
Sexually Transmitted Infections, including HIV, in the Netherlands in 2007 
Chlamydia, gonorrhoea and syphilis
In 2007, chlamydia was the most common bacterial sexually transmitted infection (StI) 
diagnosed in Dutch StI centres. Similar to previous years, infections were reported 
especially in young heterosexuals. the proportion of positive chlamydia tests among 
heterosexual men and women decreased slightly for the first time in four years (from 
10.6% to 10.1%). In 2006, this proportion had stabilized in men who have sex with men 
(MSM) with the trend continuing in 2007. the positivity rate for gonorrhoea (2.4%), 
syphilis (0.9%) and HIV (0.5%) continued to decrease in 2007. these infections were most 
frequently diagnosed in MSM.
HIV
In 2007, 306 new positive HIV cases were diagnosed in StI centres in the Netherlands. 
this number amounts to about one third of the total number of 864 positive HIV cases 
registered nationally. At the end of 2007, a total of 14,019 HIV cases in care were regis-
tered in the Netherlands. the proportion of MSM among new HIV cases rose further in 
2007. In line with previous years, concurrent StIs were diagnosed very frequently among 
MSM visiting StI centres (45%) who had known HIV positive status. In this group of men, 
Lymphogranuloma Venereum (LGV) an aggressive type of chlamydia, has been reported 
frequently since 2004; this has also been the case for hepatitis C since 2007. In this group 
of men, strengthened surveillance and innovative interventions are warranted in order 
to prevent further transmission both among MSM and to other population groups. 
Migrant populations
In some specific migrant groups in the Dutch population -- for example, people from 
Surinam, the Netherlands Antilles and Aruba -- HIV, chlamydia, gonorrhoea and syphilis 
are more common than in the autochthonous Dutch population. this indicates the need 
for targeted intervention by risk profile. 
the specialised StI centres in the Netherlands offer StI testing and care targeted at high 
risk groups. In 2007, approximately 78,000 people used this service amounting to a rise 
of 13% compared to 2006. 
Key words: HIV/AIDS, STI, surveillance, trends, the Netherlands
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pReFaCe
this annual report presents the national surveillance data and a review of the epidemiology 
of sexually transmitted infections (StI), including HIV/AIDS, in the Netherlands in 2007. 
the report aims to produce an overview of recent trends and current developments in 
the field of StI from data sources available. 
We expect that this report contributes to a better understanding of the distribution and 
determinants of StI, including HIV, in the Netherlands, resulting in further targeting of 
(preventive) interventions and assessment of their effectiveness on StI transmission. the 
information is directed at policy makers, researchers in the field of StI and related subjects 
as well as others interested in StI trends in the Netherlands. More information on StI and 
HIV in the Netherlands is available at www.soahiv.nl and www.hiv-monitoring.nl. A copy 
of this report can also be downloaded in PDF format from www.soahiv.nl. 
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SameNVattINg
In 2007 werden in totaal 78.062 nieuwe soaconsulten uitgevoerd bij de soacentra, 
waarmee het aantal bleef stijgen, met 13% ten opzichte van 2006. De soacentra richten 
zich op hoogrisicogroepen door toepassing van een landelijk geadviseerd triagesysteem. 
Deze hoogrisicogroepen, zoals mannen die seks hebben met mannen (MSM, 28% van de 
mannelijke bezoekers in 2007), personen afkomstig uit soa/hiv endemische gebieden 
(15%) en jongeren (41% beneden de 25 jaar oud), worden gratis getest. In de tweede helft 
van 2007 voldeed 94% van de soaconsulten aan de gestelde criteria voor hoogrisico of 
gaf aan anoniem getest te willen worden.
Bacteriële soa
In 2007 was chlamydia opnieuw de meest gediagnosticeerde bacteriële soa in de soacen-
tra met 7801 gerapporteerde gevallen. Het percentage positieve chlamydiatesten bij 
heteroseksuele mannen en vrouwen daalde voor het eerst in 5 jaar (10,1%). De meerder-
heid van de chlamydiadiagnoses (56%) werd bij heteroseksuele jongeren onder de 25 jaar 
gerapporteerd. Bij MSM stabiliseerde het percentage positieve chlamydiatesten in 2006 en 
deze trend zette door in 2007. LGV, een aggressieve variant van chlamydia, werd alleen 
bij MSM gevonden. Sinds de uitbraak van LGV in 2004 wordt deze infectie nog steeds 
regelmatig gevonden: in 2007 werden maandelijks 3-10 gevallen van LGV gediagnosti-
ceerd. Het percentage positieve gonorroe- en syfilistesten nam verder af in 2007 (2,4% en 
0,9%). Beide infecties werden het meest gevonden bij MSM (53% van gonorroediagnoses 
en 83% van syfilisdiagnoses) en dan vooral in de leeftijdsgroepen vanaf 35 jaar. Specifieke 
migrantengroepen (onder andere afkomstig uit Suriname, Nederlandse Antillen en Aruba) 
hadden relatief vaker een positieve testuitslag voor chlamydia en gonorroe (mannen en 
vrouwen), en voor syfilis (alleen heteroseksuele mannen) dan autochtone Nederlanders, 
wat aangeeft dat preventie gericht op specifieke groepen essentieel is. 
Virale soa
In de soacentra werden 306 nieuwe hivdiagnoses gesteld in 2007. Het percentage positieve 
hivtesten nam af voor MSM tot 2,8% en bleef stabiel bij heteroseksuele mannen en vrouwen 
(0,1%). In 2007 werden 864 nieuwe aanmeldingen van hivpositieve personen gerapporteerd 
in de anonieme nationale hivregistratie bij de Stichting HIV Monitoring. Eind 2007 waren 
in totaal 14.019 personen met hiv in Nederland geregistreerd. Het aandeel nieuw gerap-
porteerde hivinfecties bij MSM nam in 2007 verder toe tot 65% en de (mediane) leeftijd 
op het moment van diagnose nam toe tot 40 jaar. Bij bijna de helft van de hivpositieve 
MSM soacentrumbezoekers (45%) werd een soa gediagnosticeerd. Zowel in preventie als 
interventie zijn innovatieve methoden nodig om de continue soa- en hivtransmissie in 
deze hoogrisicogroep te verminderen.
De meerderheid van de heteroseksuelen met hiv rapporteerde de hivinfectie te hebben 
opgelopen in het land van herkomst: overwegend in sub-Sahara Afrika, maar ook in 
Latijns Amerika. Migratie blijft een belangrijke factor, ondanks een dalend aandeel in 
de nieuw gerapporteerde hivinfecties. 
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Het aantal diagnoses van andere virale soa steeg in 2007 licht in de soacentra. Het aantal 
diagnoses van genitale wratten – de meest gediagnosticeerde virale soa in de nationale 
soasurveillance – nam toe met 7% en het aantal diagnoses van genitale herpes (HSV) nam 
toe met 13%. Hierbij moet worden opgemerkt dat rapporteren van genitale wratten en 
HSV in het registratiesysteem vooralsnog facultatief is, waardoor het aantal diagnoses 
niet vergelijkbaar is met die van de besproken bacteriële soa en hiv. Het aantal gevallen 
van acute hepatitis B verminderde met 9% van 2006 tot 2007 in de aangifte van meld-
ingsplichtige infectieziekten. Genotype A was het meest voorkomende genotype in de 
acute hepatitis B-gevallen, net als in voorgaande jaren. In 2007 was er onder MSM een 
duidelijke stijging van het aantal gerapporteerde gevallen van acute hepatitis C opgelopen 
via seksueel contact (van 11 naar 29).
SuMMAry
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SummaRy 
With a total of 78,062 new StI consultations carried out in the national network of StI 
clinics in the Netherlands in 2007, the number continued to increase, by 13% compared 
to 2006.  the StI clinics target high risk groups by patient selection based on a standard-
ized list of criteria. High risk groups, such as men who have sex with men (MSM, 28% of 
male attendees in 2007), persons originating from StI/HIV endemic areas (15%) and young 
people (41% is under 25 years), are tested for free. In the second half of 2007 94% of clinic 
attendees fulfilled one or more of the criteria or wanted to be tested anonymously. 
Bacterial STI
In 2007, chlamydia remained the most commonly diagnosed bacterial StI in the StI centres. 
Positivity rates of chlamydia in heterosexual men and women slightly decreased for the 
first time in 5 years. the majority (56%) of chlamydia cases were diagnosed in heterosexu-
als, younger than 25 years of age. In MSM, the positivity rate stabilized in 2006 and this 
trend continued in 2007. LGV, a vicious strain of chlamydia, was found in MSM only. Since 
the outbreak of LGV in 2004, this infection continues to be reported regularly: in 2007 
3-10 cases per month were diagnosed in MSM. the percentage positive for gonorrhoea 
and syphilis continued to decrease further in 2007. Both infections were most prevalent 
among MSM (53% of gonorrhoea and 83% of syphilis cases) especially in the age groups 
of 35 years and older. Specific ethnic minorities (for instance from Surinam, the Neth-
erlands Antilles and Aruba) had higher positivity rates for genital chlamydial infection, 
gonorrhoea (men and women) and syphilis (heterosexual men only) than autochthonous 
Dutch, pointing to the need for targeted intervention by risk profile. 
Viral STI, including HIV
At the StI centres, a total of 306 new HIV cases were diagnosed in 2007. HIV positivity 
rates at the StI centres slightly decreased to 2.8% in 2007 for MSM and remained fairly 
stable for heterosexual men and women (0.1%). 
In 2007, 864 new HIV-positive persons were recorded in the anonymous national HIV 
registry of the HMF. As of December 2007, a total of 14,019 HIV cases, under medical care, 
had been recorded in the Netherlands. the proportion of MSM among HIV cases reporting 
for care increased over time, up to 65% in 2007; in addition the (median) age at diagnosis 
increased to 40 years among MSM. Nearly half of the HIV-positive MSM consulting the 
StI centres (45%) were co-infected with another StI. StI-prevention and -intervention 
programmes need to adopt innovative methods specifically aimed at bringing down the 
transmission in this high-risk group.
 
the majority of HIV-positive heterosexuals reported to have acquired their infection in the 
country of origin: mainly in sub-Saharan Africa and to a lesser extent in Latin America. 
Immigration thus remains an important contributor, although the proportion of new 
HIV cases from this origin is decreasing. 
the number of other viral StIs increased in the StI centres in 2007. the number of genital 
warts reported – the most common viral StI in the national surveillance- increased by 7% 
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and the number of cases of Herpes genitalis (HSV) increased by 13%. reporting of these 
two StI is at present not obligatory; hence the number of diagnoses is not comparable 
to the bacterial StI and HIV described above. the number of acute cases of hepatitis B 
decreased by 9% from 2006 to 2007. Genotype A was the most common type among the 
acute cases of HBV, similar to the previous years. In 2007 a clear increase in cases of acute 
hepatitis C acquired by sexual transmission was reported among MSM.
LISt OF ABBrEVIAtIONS
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LISt OF abbReVIatIONS
ACS Amsterdam Cohort Studies
AIDS Acquired Immune Deficiency Syndrom
AtHENA AIDS therapy Evaluation in the Netherlands 
CSW Commercial Sex Worker
CVB Centrum voor Bevolkings Onderzoek, research Centre for Population  
  Studies
GrAS Gonococcal resistance to Antimicrobials Surveillance programme
HAArt Highly active anti-retroviral therapy
HBV Hepatitis B virus
HCV Hepatitis C virus
HIV  Human Immunodeficiency virus
HMF HIV Monitoring Foundation
HPV Human papilloma virus
HSV Herpes simplex virus
IDu Intravenous Drug users
LGV Lymphogranuloma venereum
MSM Men who have sex with men
NA Not available
rIVM rijksinstituut voor Volksgezondheid en Milieu, (National Institute for  
  Public Health and the Environment)
StI Sexually transmitted Infections
WSW Women who have sex with women
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INtROduCtION 
this report describes current trends in the epidemiology of StIs, including HIV, in the 
Netherlands. It is prepared by the Centre for Infectious Disease Control (CIb) at the 
National Institute for Public Health and the Environment (rIVM). the CIb collaborates 
with various partners in the field of StI to collect data for surveillance and to generate 
insights into trends and determinants: the StI centres, the HIV Monitoring Foundation 
(HMF), public health laboratories and other health care providers.
Available data on StI from surveys, national registries and cohort studies are compiled 
in this report and provide an overview of the current status of StI, including HIV in the 
Netherlands. Preliminary data have been presented in the thermometer (April 2008) 
and were discussed at the annual expert meeting on the surveillance of StI and HIV in 
June 2008. 
Outline of the report
In Chapter 1 the methodology of StI surveillance in the Netherlands is described, includ-
ing all sources of data used for this report. In Chapter 2 the characteristics of StI clinic 
attendees are described for 2007. Chapter 3 deals with bacterial StI (chlamydia, gonor-
rhoea and syphilis) in the national surveillance of StI and Chapter 4 focuses on viral StI, 
including HIV, hepatitis B, C, genital warts and genital herpes. In Chapter 5 an overview 
is given of specific high risk groups in the Netherlands. Conclusions and recommenda-
tions are described in Chapter 6. 
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metHOdOLOgy OF StI aNd HIV SuRVeILLaNCe1 
National surveillance at StI centres1.1 
Since 1995 StIs are registered into an StI registration at the rIVM in the Netherlands. 
In 2003, an StI sentinel surveillance system was put in place, which reached national 
coverage in 2004 with inclusion of all major StI centres. Since January 2006, reporting 
into the national StI surveillance system is organised in eight regions, with each one StI 
centre that is responsible for regional coordination of StI control (Figure 1.1). In total, 
32 specific StI centres, mostly within the municipal health services, provide low thresh-
old StI/HIV testing and care, free of charge, targeted at high risk groups and persons 
who want to be tested anonymously. All consultations and corresponding diagnoses are 
reported online to the Centre for Infectious Disease Control for surveillance purposes. 
the unit of reporting is ‘new StI consultation’, in which laboratory testing and/or medical 
examination is carried out. 
In this report, the results of national surveillance of StI centres are presented with respect 
to the number and nature of new consultations and diagnoses. trends in postivity rates 
by risk profile (based on demographic and behavioural indicators) in time are based on 
data from the StI centres in the national surveillance since 2004. Where data were not 
complete for a specific period or StI centre, this is indicated. We focus on the major 
bacterial and viral StI, including HIV infection. 
Regio Oost
GGD Regio Nijmegen
Regio Limburg
GGD Zuid-Limburg
Maastricht
Regio Noord
GGD Groningen
Hulpverleningsdienst 
Groningen
Regio Utrecht 
GG&GD Utrecht
Regio Noord Holland Flevoland
GGD Amsterdam
Regio Noordelijk Zuid Holland
GGD Den Haag, dienst OCW
Regio Zuidelijk Zuid Holland
GGD Rotterdam e.o.
Regio Zeeland Brabant
GGD Hart voor Brabant,
Den Bosch
Figure 1.1: Eight regions with coordinating STI centre indicated
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the reporting of consultations is facilitated by a web based application (SOAP). Individual 
anonymised reports contain epidemiological, clinical and microbiological data on a wide 
range of StI. until recently, reason(s) for StI consultation were reported. Since July 2007 
however, the case report changed to include specific data on indicators for high risk, to 
assist efficient targeting of services. Currently, persons matching one of the following 
criteria: (1) presence of StI-related symptoms, (2) notified or referred for StI-test, (3) age 
below 25 years, (4) MSM, (5) involved in commercial sex, (6) originating from an HIV/StI 
endemic area or (7) number of sexual partners in previous six months above average (three 
or more) are considered to be at increased risk for StI acquisition and in order to prevent 
ongoing transmission they can be tested free of charge in the StI centres. Furthermore, 
persons who indicate they want to be tested anonymously can also make use of the StI 
centres to guarantee ‘low threshold’ StI care.     
Behavioural surveillance
In 2006 a limited set of key indicators was added to the StI surveillance.1 these include: 
the number of partners in the last six months, condom use at last sexual intercourse 
and sexual contacts abroad in the last three months. StI centres and individual clinic 
attendees are free to decide to ask or answer these questions. In addition, other data such 
as the date and result of previous HIV-test and previous StI diagnosis were collected to 
support behavioural surveillance linked to epidemiological and microbiological outcomes. 
Behavioural indicators from the StI centre Amsterdam are (not yet) available in the SOAP 
database. In the text and tables of the report, non-availability of data is indicated where 
necessary.
antimicrobial resistance of 1.2 
gonococci in the Netherlands
In 1999, the surveillance of antibiotic resistance of gonococci at national level was discon-
tinued and since then insight in gonococcal susceptibility patterns has been limited. 
Concern for increasing resistance to quinolones at (inter)national level led to a rIVM 
survey of resistance of gonococci in 2002.2 the results demonstrated the need for a 
nationwide surveillance of gonococcal antimicrobial resistance. 3-6 In 2006, the Gonococcal 
resistance to Antimicrobials Surveillance programme (GrAS) has been implemented in 
the Netherlands. this surveillance consists of systematically collected data on gonorrhoea 
and resistance patterns linked with epidemiological data. Participants are StI clinics and 
associated laboratories.
National HIV screening 1.3 
Blood donors have been screened on HIV since the first HIV test became available in 
1985 (www.sanquin.nl). Standard HIV screening is offered to all pregnant women since 
January 2004 (opting out method). the test is offered in the first trimester of pregnancy 
as part of the prenatal screening that includes also hepatitis B (since 1990) and syphilis 
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(since 1960).7 Currently, nationwide data are being analysed and are not yet available for 
publication. Since 2006, the Centre for National Screening Programmes (CVB) is coordi-
nating the screening programme on infectious diseases in pregnant women. the Centre 
for Infectious Disease Control is currently preparing an evaluation of this programme. In 
Amsterdam, pregnant women have been tested for HIV from 1988 onwards in a sentinel 
surveillance study in two hospitals and an abortion clinic. Since 2003, all pregnant women 
in Amsterdam are screened for HIV and these data are described.8 
anonymous HIV surveillance at StI clinics1.4 
HIV surveillance among StI clinic attendees is conducted since 1991 in Amsterdam and 
since 1994 in rotterdam. In Amsterdam, two cross sectional studies including 1000 visitors 
each are conducted every year. Since 1997, HIV testing is promoted at all StI clinics in 
the Netherlands as part of an active HIV testing policy that was implemented following 
the accessibility of Highly Active Antiretroviral therapy (HAArt). 
HIV incidence data1.5 
HIV incidence data are obtained from the Amsterdam Cohort Studies (ACS) on HIV/AIDS, 
which started in 1984 among MSM and in 1985 among IDu. these cohorts give insight 
in HIV rises in an early state in a specific population and are supportive for prevention 
activities to respond effectively to the ongoing HIV epidemic. From 1995 and 1998, special 
recruitment started among young (<30 years) MSM and IDu, respectively. However, since 
April 2006 participation is open again for MSM of all ages with at least one sexual partner 
in the preceding six months. the ACS, a collaboration between the Amsterdam Health 
Service, the Academic Medical Centre of the university of Amsterdam, the Sanquin Blood 
Supply Foundation and the university Medical Centre utrecht, are part of the Netherlands 
HIV Monitoring Foundation and financially supported by the Netherlands Institute for 
Public Health and the Environment. [www.amsterdamcohortstudies.org]. 
National registration of HIV treatment centres1.6 
From January 2002, an anonymous HIV/AIDS reporting system for patients enter-
ing care was implemented in the Netherlands. Longitudinal data of all newly regis-
tered HIV infected individuals are collected by the HIV Monitoring Foundation (HMF, 
www.hiv-monitoring.nl). the goal of HMF is to monitor HIV infected individuals regis-
tered in the 25 recognised HIV treatment centres (including four children’s centres) in 
the Netherlands to study changes in the epidemic, the natural history of HIV and the 
effects of treatment. 
All HIV infected individuals registered in this cohort are followed prospectively from the 
time of reporting for care. HIV infected individuals in care, who were diagnosed prior to 
the start of HMF, were as far as possible included in the cohort retrospectively. HMF largely 
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follows the organisational structure that had been established for monitoring HIV in the 
AtHENA project, a clinical study following HIV infected individuals who are treated with 
HAArt. the HIV cases diagnosed before 1996 only include persons who survived up to 
the start of the AtHENA project in 1996. the epidemiological data on newly reported HIV 
infections, as well as trends in new AIDS diagnoses after 2000, are reported in collabora-
tion with the Centre for Infectious Disease Control at the rIVM.
Between 1987 and 2002, AIDS cases were reported on a voluntary basis to the Inspec-
torate of Health (national AIDS registry, IGZ). With the start of the HIV/AIDS monitoring 
system in 2002 by HMF, the national AIDS registry was ended. In this report, AIDS cases 
from 1999 or earlier are obtained from the AIDS registry. From 2000, AIDS cases from 
the HMF monitoring system were used. Data on deaths among HIV patients (including 
AIDS patients) were obtained through the HMF (≥ 2002 and previously from National 
Statistics Netherlands (www.cbs.nl) <2002).  
blood donors1.7 
Since 1985 blood donated by (new and regular) blood donors is screened for HIV, hepa-
titis B and C and syphilis and positive blood is not used for blood transfusion. Volunteers 
are checked according to quality and safety guidelines and people who report specific 
risk factors for blood transmitted infections are not accepted as donors. records are 
kept in the national donor register, which provides good information on the prevalence 
and incidence of these infections in a low-risk population. Data are reported from 1998 
onwards. Prevalence an incidence were calculated with the data provided by the blood-
bank register (www.sanquin.nl). 
Notification of hepatitis b and C 1.8 
the compulsory notification of newly diagnosed acute hepatitis B and C virus (HBV and 
HCV) infections (since 1976) and chronic HBV infections (both since April 1999, but 
reporting of chronic HCV cases was stopped in 2005) includes epidemiological data on 
the occurrence of disease within specific risk groups. Since 2002, all public health services 
notify HBV and HCV cases by using the web based application Osiris. 
molecular epidemiology of acute HbV1.9 
In 2004, a study was initiated to evaluate the success of the HBV vaccination among high 
risk groups, in collaboration with the Municipal Health Services of Amsterdam and rotter-
dam. trends in HBV infections are studied and additionally blood samples are collected 
from all newly diagnosed acute HBV patients for genotypic analysis, to get more insight 
in the transmission networks within and between HBV risk groups in the Netherlands, 
and in the effectiveness of the vaccination campaign.  
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StI CLINIC atteNdeeS2 
key points2.1 
In 2007, 78,062 new consultations were registered in the national surveillance of StI • 
centres.
the number of consultations increased by 13% in 2007 compared with 2006.  • 
Characteristics of clinic attendees were as follows: young age (41% under 25 years old), • 
Dutch origin (80%), MSM (28%) and commercial sex workers (9%), 13% had a history of 
StI and 50% was not previously tested for HIV.
StI consultations2.2 
In 2007, 78,062 new consultations (increase of 13% compared to 2006) were registered 
within the national surveillance of StI centres; 39,824 (51%) among men, 38,209 (49%) 
among women and 28 (0.0%) among transsexuals (Appendix table A.1). the StI centre in 
Amsterdam reported 34% of these consultations. 
Of the attendees, 84% had both an StI examination and an HIV test, 15% only had an StI 
examination (tested for chlamydia, gonorrhoea, syphilis or hepatitis B) and 1% only an 
HIV test (Figure 2.1). Of the 15% not tested for HIV, 12% were known HIV positives.
Over the past years the number of consultations has risen continuously (Figure 2.2). In 
January 2006, the surveillance system changed from an StI sentinel surveillance network 
to a surveillance network of all StI centres in 8 regions in the Netherlands. In addition, 
Figure 2.1: Distribution of consultations, national surveillance STI centres, the Netherlands, 2007
HIV test 
STI examination 
Both 
No test 
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the financing system for StI consultations has changed. this may slightly limit direct 
comparison of data with previous years (see chapter 1 on Methodology).
Characteristics of attendees2.3 
Of all male attendees, 28% (n=11,048) reported sex with men (Appendix table A.5) and of 
female attendees, 5% reported sex with women (n=1995). Eight percent of men (n=3,113) 
reported visiting a commercial sex worker (CSW) in the previous six months (Appendix 
table A.6) and 9% of women (n=3,395) worked as a CSW the past six months. recent inject-
ing drug use (past six months, variable not available –NA- from StI centre Amsterdam) 
was reported by 0.2% of the attendees (n=133), but these data were missing for 4% of the 
attendees (Appendix table A.7).  Overall, 13% (n=6607) of the attendees (NA Amsterdam) 
reported a history of StI (gonorrhoea, syphilis or genital chlamydial infection); 13% of 
all men and 12% of all women. 
the age distribution differed for men and women: among men the largest groups were 
those of 20-24 years and 25-29 years old (24% and 21% respectively) and among women 
20-24 years (41%, followed by 25-29 years: 22%) (Appendix table A.3). 
About 80% of the clinic attendees were of Dutch origin (2006: 81%); for women this was 
81% and for men 79%. Other groups originated from Surinam (5%), sub-Saharan Africa 
(2%), Asia (2%), Eastern Europe (2%), other European countries (2%), the Netherlands Antil-
les (2%), Latin America (2%), Morocco and other North African countries (1%), turkey (1%) 
and other (3%) (Appendix table A.4). 
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Footnote: 1995-2002: StI registration; 2000*: StI clinic of Erasmus Medical Centre rotterdam 
was included; 2003: Implementation of StI sentinel surveillance network, 2004-2007: National 
StI surveillance network.
Figure 2.2:  Number of consultations in the STI registration in the Netherlands, 1995-2007
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Of the attendees, 50% (n=38,832) were never tested for HIV antibodies before. Forty 
six percent (n=36,016) previously tested HIV negative (48% men, 45% women) and 1.9% 
(n=1,470) previously tested HIV positive (3.6% men, 0.1% women) (Appendix table A.8). 
Eighty five percent of the attendees who were never tested for HIV were tested on HIV 
in the current consultation.
Reasons for consultation 
Due to changes in the registration system the ‘reason for StI consultation’ was reported 
only from January till June in 2007 (table A.10a, NA Amsterdam). the most commonly 
reported reason for StI consultation in that period was risk behaviour (43% of all clients), 
followed by symptoms (27%) and a new sexual relationship or uncertainty (both 21%). 
Other reasons for consultations were anxiety or concern (13%), (periodic) screening (11%), 
notification by (ex)partner or social worker (9%), risk behaviour of partner and partner has 
symptoms (8%), HIV test (6%), hepatitis B vaccination (2%) or condom failure (2%). 
Indication criteria for high risk
From July 2007, specific questions were included in SOAP about the criteria used to indi-
cate whether the clinic attendee belongs to the targeted high risk group or not (Appendix 
table A.10b). the most commonly reported indication criteria were the preference to be 
tested anonymously (52%, NA Amsterdam) and three or more sex partners in the previous 
six months (45%, NA Amsterdam). the age criterion was applicable to 41% (younger than 
25 years old) and this was higher for women than men (55% vs. 29%). Further frequently 
reported indications were partner belonging to a risk group (28% NA Amsterdam), having 
symptoms (22% NA Amsterdam), attendee originating from a StI/HIV endemic area (15% 
non-western ethnicity), and MSM (14%). In the second half of 2007, 6% of the visitors did 
not fulfil one of the inclusion criteria.
behavioural surveillance in StI centres2.4 
the response rate to the optional behavioural questions ranged from 73% to 87% per ques-
tion (NA Amsterdam and utrecht). twenty seven percent of the attendees used condoms 
in their last sexual encounter: 31% of men and 24% of women.  ten percent of men and 6% 
of women had sexual contacts abroad in the last 6 months. Most reported countries for 
men were thailand, Germany and Spain and for women turkey, Spain and Netherlands 
Antilles. Eight percent had an StI before, 9% of women and 8% of men (NA Amsterdam). 
the median number of partners in the past six months was two for both men and 
women. the mean number of partners was 3.8, with a significant difference between 
heterosexual men (3.0 ± SD 4), women (3.7 ± SD 15) and MSM (6.9 ± SD 13); means are 
influenced by a small group of persons reporting very high  partner rates, especially in 
women (CSW) and MSM. the proportion of persons reporting four or more partners in the 
last six months was 14% for women and 22% for heterosexual men, while this was 50% in 
MSM. Five percent of attendees indicated to be ‘swinger’ (= part of a couple involved in 
hetero- and bisexual contacts with other persons or couples); this proportion was similar 
in men and women.
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baCteRIaL StI3 
Chlamydia and Lymphogranuloma venereum3.1 
key points3.1.1 
Genital chlamydia infection remained the most commonly diagnosed bacterial StI: • 
7,801 cases were seen in the national surveillance StI centres and 3,187 in the labora-
tory surveillance.
the main burden of disease is carried by the young heterosexual population (53% • 
under 25 years).
After a gradual rise in the previous years, the chlamydia positivity rates decreased • 
slightly, from 10,6% to 10,1%  in heterosexual men and women from 2006 to 2007. In 
MSM it stabilised at the same high level (10,1%).
Highest positivity rates were observed in teenage girls and boys (15-19 years), young • 
heterosexual men (20-24 years) and adult MSM (30-39 years), as well as men and 
women from Surinam and the Netherlands Antilles.
the number of chlamydia infections reported in anal and oral samples increased in • 
women and MSM during the past four years.
Chlamydia cases are more likely to be HIV-positive and to have co-infections with • 
gonorrhoea and syphilis than persons testing negative for chlamydia.
Recent trends chlamydia 3.1.2 
Genital chlamydia, a bacterial sexually transmitted infection caused by Chlamydia tracho-
matis (hereafter referred to as chlamydia), remained the most common diagnosis in StI 
centres in the Netherlands. In 2007, 7,801 genital chlamydia infections were diagnosed 
(3,908 in men and 3,893 in women) in the regional StI centres (Appendix table A.11a), 
representing 44% of all positive StI diagnoses. Chlamydia was tested in 99% of persons 
visiting the StI-centres; the overall positivity rate was 10%.
Gender, sexual preference and age group
reported chlamydia cases are concentrated in the younger age groups in both sexes. the 
major part of chlamydia cases (53%) in 2007 was reported from the population under 
25 years old (Appendix table A.12). Cases were equally divided over the sexes. In men, 28% 
of cases were reported in MSM and in women 4% in women who have sex with women 
(WSW, 5% of female attendees), hence homo- or bisexual preference does not increase 
the risk for chlamydia in men or women.
the positivity rate in women was 10.1% overall, higher among heterosexual women 
(10.4%) than among WSW (7.3%). In men, 10% of chlamydia-tests were positive, similar in 
heterosexual men and MSM (9.9% and 10.1%, respectively).
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the highest positivity rate was seen in teenage girls under 20 years old (17% in 15-19 years 
old). For heterosexual men the positivity rates were higher in teenagers as well as young 
adolescents, i.e. both under and over 20 years old (14% positivity in 15-24 years old). In 
older age groups, chlamydia rates were clearly higher in MSM than in heterosexual men 
and women (12% in 30-34 years old; see Figure 3.1)
Location of infection 
Sampling for chlamydia tests from one or more locations is performed when deemed 
necessary by the consultant doctor or nurse. In women, 89% of positive diagnoses were 
found in urine/vaginal/cervical samples and 7% in anorectal. In heterosexual men, nearly 
100% of positive results were in urine/urethral samples; in MSM, 59% were anorectal and 
38% urine/urethral. Oral chlamydia infections were seen in 3.3% of female diagnoses, 0.4% 
of those in heterosexual men and 2.9% of diagnoses among MSM (Appendix table A.11b). 
Among MSM, 9% of persons with a chlamydia infection was infected at more than one 
location, whereas this proportion was 5% for women and 0.2% for heterosexual men.
Regional pattern 
the eight regional centres of the national StI surveillance reported positivity rates in the 
range of 8.7% to 11.7% (Figure 3.2). the diagnoses were fairly unevenly distributed across 
the Netherlands (range: 320 to 3,082 cases reported per StI regional centre). Positivity 
rates tended to be higher in clinics located in highly urbanised areas in the western part 
of the country but also in the StI centres in the eastern part.  
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Figure 3.1: Positivity rate of chlamydia tests by gender/sexual preference and age-category, natio-
nal surveillance STI centres, the Netherlands, 2007
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Trends in time 
After three years of gradual increase, the chlamydia positivity rate now decreased signifi-
cantly in heterosexual men and women (p<0.001), while it remained at a similar level in 
MSM. the absolute number of chlamydia cases diagnosed in the StI centres still increased 
with 9%. this rise in absolute numbers was lower in heterosexual men than in women 
and in MSM: 7% versus 10% and 15% and was due to the increased number of consulta-
tions and proportion tested for chlamydia (from 97.1% to 98.7%) rather than a rise in the 
proportion of positive diagnoses (see Figure 3.3).
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Figure 3.2: Positivity rates for genital chlamydial infection by STI region, the Netherlands, 2007
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Figure 3.3: Total number and positivity rate of diagnoses of genital chlamydial infection by 
gender/sexual preference, national surveillance STI centres, the Netherlands, 2004-2007
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the trends for the eight StI regions show that the chlamydia positivity rates increased from 
2004 to 2007 in the more rural areas, i.e. Zeeland/Brabant, Oost, Limburg and also utrecht, 
while regions with large cities, i.e. Zuidelijk Zuid-Holland, Noordelijk Zuid-Holland and 
Noord-Holland Flevoland did not show a clear increase, and neither did region Noord 
(Groningen). the ‘urban centres’ see more chlamydia cases, but the proportion seen in 
the ‘rural centres’ has increased from one fifth to one third in this 4-year period.
From 2004 to 2007, the proportion of chlamydia infections diagnosed from oral or anal 
samples increased for women and for MSM (from 6% to 11% in women and from 55% to 
62% in MSM). this is probably influenced by increased sampling from these locations; data 
on the negatives or the total number of tests by location is incomplete (only available 
from 2006 and for Amsterdam from 2007).
Risk groups 
StI clinic attendees of specific ethnic groups had more often a genital chlamydial infec-
tion than autochthonous Dutch. About 75% of the diagnoses in men were made in Dutch 
men and 81% in Dutch women; most diagnoses among non-Dutch were from persons 
originating from Surinam and the Netherlands Antilles/Aruba (14% in heterosexual men 
and 8% in women; Appendix table A.13). the positivity rate in heterosexual men was 
higher among these groups (16% and 19%) as compared to the rate in Dutch men (9%, 
p<0.001). In women the positivity rate was also higher among women from Surinam and 
the Netherlands Antilles/Aruba (14% and 16%, respectively) than in Dutch women (10%, 
p<0.001). reported condom use at last sexual contact was lower for chlamydia positives 
compared to chlamydia negatives (21% vs. 28%, p<0.001).
Persons visiting the clinic indicating they were working as a commercial sex worker 
(CSW) or had visited a CSW in the past six months did not show a higher infection rate 
with chlamydia. Among men, 4.8% of the chlamydial infections were diagnosed in men 
who had recent contact with CSW (positivity rate 6.1% in 3,068 chlamydia tests in this 
group).  In women 6.3% of the chlamydial infections were diagnosed in CSW (7.4% posi-
tive of 3,333 chlamydia tests in CSW, see also Appendix table A.15). 
Co-infections
In 3% (n=260) of the cases of chlamydial infection the diagnosis was made in individuals 
who were HIV positive (known HIV infected, total n=837). Of the individuals diagnosed 
with chlamydial infection, 55% were never tested for HIV before (Appendix table A.17). 
Among chlamydia-cases 47 persons were found to have a new HIV-infection, which 
represents 16% of all new HIV-infections found in the StI surveillance system in 2007; 
the majority of them was MSM (43/47), age averaging 37 years.
Of the reported chlamydia cases 7% also had an infection with gonorrhoea and 1% had a 
syphilis co-infection. these cases encompass 29% of gonorrhoea and 14% of syphilis cases 
found in 2007. A history of gonorrhoea, infectious syphilis or chlamydial infection was 
reported by 15% of the individuals with genital chlamydial infection: 17% for men and 
13% for women (Appendix table A.18). Co-infections of gonorrhoea and chlamydia were 
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more often seen in MSM (46% of cases), especially in the age-group 30-44 years and in 
women (31%), generally of younger age (16-24 years old).  
Laboratory surveillance3.1.3 
Within the laboratory surveillance of the ISIS project, the diagnosis of genital chlamyd-
ial infection is defined as follows: culture positive or PCr positive or hybridisation test 
(including Genprobe) positive. All test results are counted only once per individual and 
an individual can only be counted as positive once in 60 days. the data presented here 
are from nine laboratories reporting data continuously for the period 2002 to 2007 and 
one additional laboratory which was connected from 2003. together these laboratories 
covered nearly 5% of the Dutch population. Since 2007 the ISIS project in its original 
form is not supported any longer (a renewed project awaiting), but the laboratories still 
continued to report chlamydia accurately.
From 2002 to 2007, 196,138 tests to diagnose infection with Chlamydia trachomatis were 
carried out, of which 14,027 were positive (7.1%). the number of cases reported has 
increased yearly (Appendix table 3.1). In 2007, 3,187 positive cases were reported, with 
a positivity rate of 7.5%; in women the positivity rate was 6.2% and in men 10.5%.
Table 3.1: Number of tests and positive results for chlamydial infections reported from sentinel 
laboratories from 2002 to 2007 (Source: RIVM-ISIS)
2002 2003 2004 2005 2006 2007
Number of tests 16,417 24,475 35,898 36,969 40,530 42,649
Positive test result 1081 1632 2362 2811 2954 3187
Percentage positive 6.6 6.7 6.6 7.6 7.3 7.5
*In 2003 one large laboratory was connected
the origin of the sample, i.e. the health provider/organisation requesting the laboratory 
for a test, is recorded in ISIS. the majority of patients were seen in the hospital, either 
inpatient or outpatient, at the GP (Appendix table 3.2) and some at Public Health Services 
(GGD) not connected to the StI surveillance system. the positivity rates vary according to 
the origin: higher in PHS and policlinic, followed by GP, low in hospitalized patients.
Table 3.2: Number of tests and positive results for chlamydia infections reported from laborato-
ries for different patient venues in 2007 (Source: RIVM-ISIS) 
Hospital 
inpatient
Hospital 
outpatient
GP PHS (GGD) total
Number of tests 6,771 10,108 18,933 4,366 4,2649
Positive test result 184 822 1633 376 3187
Percentage positive 2.7 8.1 8.6 8.6 7.5
the positivity rate in this population is higher among men than women (11% versus 6%, 
p<0.001), which is different from the national surveillance StI centres, but the cases 
show a similar age distribution as in the StI surveillance: the peak positivity for women 
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is at the age of 16-17 years and for men at 18-19 years. In the laboratory information on 
sexual preference is not available.
Data from the weekly virological reports, which report the total number of Chlamydia 
trachomatis positive tests, were analysed from 17 laboratories (consistently reporting since 
2000, covering an estimated 40% of the cases 9), show that the number of chlamydia cases 
found has increased yearly by about 15% during the last 8 years. there is overlap in the 
laboratories reporting in this system and the laboratories connected to the StI-centres.
Lymphogranuloma venereum3.1.4 
Lymphogranuloma venereum, LGV, is caused by specific subtypes of Chlamydia trachomatis 
(serovars L1, L2 and L3). In 2004 an outbreak occurred in the Netherlands among MSM 
who were predominantly HIV-positive. Since then, surveillance for LGV intensified.10 In 
2007, the acceptability of this enhanced LGV surveillance in 2004-2005 was evaluated. 
Information from enhanced LGV surveillance was available for 34 (33%) of 104 cases 
during that period. the enhanced LGV surveillance was generally regarded as adequate, 
but it was limited by the low completeness. Following this evaluation, the additional 
enhanced surveillance was discontinued and the routine StI surveillance now includes 
LGV diagnosis LGV cases continued to be detected after the outbreak, which justifies 
alertness for LGV in the StI surveillance in the Netherlands.11
During 2007, the number of cases of LGV stayed relatively high in comparison to the 
previous two years (see Figure 3.5). the total number of LGV cases reported in 2007 was 
69. the majority of the cases (74%) were reported by the urban StI centre in Amsterdam. 
the patients showed a similar profile to that in the beginning of the outbreak.12 All cases 
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Figure 3.4: Number of positive test results for chlamydia trachomatis from 17 hospital- and 
regional laboratories, 2007 (Source: weekly virological reports, 2000-2007)
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were in MSM (except one unidentified), 67% were HIV positive, 77% were of Dutch origin 
and the mean age was 40 years (range 22-69). Concurrent StI were frequently diagnosed: 
32% (22/69) had gonorrhoea, 10% had infectious syphilis. the LGV infections were all 
diagnosed in anorectal samples. 
In March 2007 one LGV case was found in a ‘swinger’, a man with a steady female partner 
who had sex with other couples including also men. Although no similar cases have been 
reported so far, this incident showed that LGV could become a generalized infection if 
transmission into the heterosexual community occurs via this group of swingers. 
discussion3.1.5 
Chlamydia positivity rates decreased in 2007 for heterosexual men and women after 
a (gradual) increase in the last 5 years. In MSM the increasing trend stabilized in 2006. 
the prevalence of LGV remained high in 2007, since the renewed increase in cases since 
August 2006. 
the main burden of chlamydia infection is carried by the young heterosexual population. 
young adolescents under 20 years old in the StI centre most frequently tested positive 
for chlamydia. this pattern has been observed in recent prevalence studies as well.13 the 
urban StI centres generally report higher numbers of chlamydia, but the positivity rate in 
more ‘rural’ centres is increasing towards the same level. Positivity rates remained higher 
in migrant groups of Surinam/the Netherlands Antilles. In the group of MSM at the StI 
centre, the 30+age groups seem to be more involved in the transmission of chlamydia. 
LGV transmission is restricted to this group exclusively.
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Figure 3.5: Number of cases of Lymphogranuloma venereum diagnosed per month in the STI 
surveillance system, the Netherlands, 2004-2007
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the data from the laboratory surveillance showed somewhat lower positivity rates for 
ambulant patients in the hospital and from GP practices. the positivity among men seen 
in the GP practice is higher than among women. Women might be more regularly tested 
for check-ups (i.e. with (foreseen) pregnancy) and for control or out of concern, whereas 
men might come primarily when symptomatic. Preliminary data from the national surveil-
lance of GP practices indicate that GP’s are responsible for an estimated 100-150,000 StI 
related consultations per year (data Landelijk Informatie Netwerk Huisartsenzorg (LINH), 
in preparation) and reported increasing numbers of chlamydia especially in men.14 More 
detailed data from the national GP surveillance will become available in 2008.  
Genital chlamydia is the most commonly reported bacterial StI, despite the lack of symp-
toms in the vast majority of people infected (especially women). the possible consequences 
of untreated infection in women are of great concern. these include pelvic inflamma-
tory disease (PID), which can lead to pelvic pain, ectopic pregnancy and infertility.15, 16 
Chlamydia infected attendees are more likely to have other concurrent StI and they are 
at a higher risk to get an HIV infection17, as was also shown in the StI surveillance data 
presented here. It is necessary to reduce the burden of chlamydia, especially in the young 
heterosexual population. Systematic screening could be a way to timely diagnose both 
symptomatic and asymptomatic cases.18 In 2008 a large scale population-based chlamydia 
screening intervention has started in Amsterdam, rotterdam and part of south Limburg, 
which will continue until 2010. the Public Health Services invite all people from 16 to 29 
years old to be tested for chlamydia. testkits are delivered at home, communication is via 
the internet. Positive cases get a referral letter to see their GP for treatment. Depending 
on the effectiveness and the feasibility (evaluated by the rIVM), the intervention may 
thereafter be applied in other regions of the country.
In other European countries genital chlamydia infection is also the most commonly 
reported bacterial StI. Increasing trends have been observed since the mid-1990s. this is 
influenced by the increasing number of tests performed and the availability of improved 
tests. In the uK and Northern Ireland positivity rates have tripled since 1990, whereas 
in Sweden, Denmark and Norway the positivity rates have clearly increased since the 
mid-1990’s.19 Also in the uS the incidence of chlamydia is high.20 
In 2006, a Chlamydia trachomatis variant was reported from Sweden, with a specific muta-
tion (base pair deletion) in the target area of several commercially available PCr tests to 
diagnose urogenital chlamydia infections, also those frequently used in the Netherlands. 
At the StI clinic in Amsterdam, a comparative study in 2006, involving several C. tracho-
matis PCr procedures found no cases of infections with the Swedish chlamydia variant 
among 515 visitors who tested positive for chlamydia.21 Further comparative studies in 
2007 did not detect the Swedish C. trachomatis variant in the Netherlands.22, but in 2007 
one case was reported from a Dutch person with a Swedish partner. PCr tests have been 
adjusted so the Swedish variant will be detected in routine surveillance. Continuing 
alertness is required to prevent the spread of a new mutated strain not detectable by 
available commercial tests. 
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gonorrhoea3.2 
key points3.2.1 
In 2007, 1,827 diagnoses of gonorrhoea were made in the national surveillance of StI • 
centres in the Netherlands (men: 77%, women: 23%).
In women, two thirds of the cases were among attendees younger than 25 years.• 
Most gonorrhoea cases were from the Netherlands followed by cases from Surinam, • 
the Netherlands Antilles or Aruba.
964 diagnoses of gonorrhoea were made in MSM, accounting for 69% of cases in • 
men.
Double infections were found in 15% of all gonorrhoea cases, 2% had a triple infec-• 
tion.
In a survey among public health laboratories, an increase of ciprofloxacin resistance • 
was reported from 6.6% in 2002 to 38.0% in 2006.
results from the nationwide surveillance of gonococcal antimicrobial resistance (GrAS) • 
showed a high prevalence of ciprofloxacin resistance in MSM (52%) and in heterosexu-
als from Eastern Europe (77%), and prevalence was low in heterosexuals from Surinam 
and the Netherlands Antilles (7%).
Recent trends gonorrhoea3.2.2 
In 2007, 1,827 diagnoses of gonorrhoea were reported (1,404 in men and 423 in women) 
in all StI centres (Appendix table A.11a), representing 10% of all StI diagnoses. Gonorrhoea 
was tested in 99% of all visitors of the StI centres, with an overall positivity rate of 2.4% 
(the percentage of positive tests to the total number of gonorrhoea tests).
Gender, sexual preference and age group
In women, most diagnoses were found among clinic attendees aged 20-24 (44%) and 
15-19 (22%). In the older age groups the number of infections was lower. In men, most 
diagnoses were made in men aged 35-39 years (17%) and 40-44 (13%) (Appendix table 
A.12). Of all diagnoses in men, 69% (n=964) were MSM and 31% (n=438) heterosexual 
men (Appendix table A.14). 
Positivity rates were much higher among MSM (8.9%) than among heterosexual men 
(1.5%) and women (1.1%). the highest positivity rate was found in MSM aged 25-29 years 
(11.1%).  In heterosexual men, the highest percentages were found in the age groups 
15-19 years and 50-54 years: 2.3% and 1.9% respectively. In women the highest percent-
ages were found in the age groups <15 and 15-19 years, 5.7% and 1.9%, respectively 
(Appendix table A.19).
Location of infection 
Samples for gonorrhoea include urethral/cervical by default as well as those taken from 
other locations when indicated (policy differs by StI centre). In women, most infections 
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were diagnosed urethral/cervical (67%). Anorectal infections and oral infections were 
found in 16% of the women. In heterosexual men, 98% of the infections were urethral and 
2% oral. In MSM, anorectal infections were diagnosed most frequently (46%), followed by 
urethral infections (36%). Oral infections were diagnosed in 18% of the MSM (Appendix 
table A.11c). 
Infections at more than one location were found frequently: 15% of all gonorrhoea cases 
were infected simultaneously on two locations and another 2% was infected on three 
locations (table 3.3). 
Table 3.3: Infections by location with gonorrhoea by gender and sexual preference, 2007.
 MSM Heterosexual 
men
Women total
urethr/cervical & anorectal 84 (8.7%) 0 43 (10.2%) 128 (7.0%)
urethr/cervical & oral 47 (4.9%) 3 (0.7%) 34 (8.0%) 84 (4.6%)
Anorectal & oral 52 (5.4%) 0 4 (0.9%) 57 (3.1%)
urethr/cervical & anorectal & oral 23 (2.4%) 0 16 (3.8%) 39 (2.1%)
Positivity rates per location differed per risk group. In women, positivity rate was highest 
in anorectal infections: 1.2%, followed by urethral/cervical and oral infections (both 0.9%). 
In heterosexual men the positivity rate for urethral infections was 1.5% and for oral 
infections 0.8%. For MSM the rate was highest for anorectal infections (6.7%), followed by 
urethral infections (4.0%) and oral infections (2.6%).
Regional pattern 
the eight regional centres in the national StI surveillance reported positivity rates for 
gonorrhoea in the range of 0.9% to 3.0% (Figure 3.6). 
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Figure 3.6: Positivity rates of gonorrhoea by STI centre, STI surveillance network, the Nether-
lands, 2007
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Trends in time 
the number of gonorrhoea tests increased with 39% from 2004 to 2007. However, posi-
tivity rates in women decreased from 1.5% in 2004 to 1.1% in 2007. In heterosexual men 
there was also a decrease: from 2.7% in 2004 to 1.5% in 2007. In MSM the positivity rate 
decreased from 10.8% in 2004 to 8.9% in 2007 (Figure 3.7). 
Risk groups
About 68% of the diagnoses in men were made in Dutch men, 59% in Dutch women 
(Appendix table A.13). the mean positivity rate among Dutch cases was 1.9%. Among 
migrant populations, most diagnoses were made in cases from Surinam, the Netherlands 
Antilles and Aruba (13%, positivity rate 5.0%). Positivity rates were also high in cases from 
North Africa/Morocco (4.5%) and Eastern Europe (4.4%).
In men, 5% of the infections were diagnosed in patients who had recent (in the previous 
six months) contact with CSW, whereas for women 20% were diagnosed in CSW (Appen-
dix table A.15). Positivity rate among CSW was 2.5% compared to 1.0% among non CSW 
(p<0.001). the positivity rate among heterosexual men who recently visited a CSW was 
1.9% compared to 1.5% in heterosexual men not reporting CSW visits.  In 14% (n=263) of 
the gonorrhoea cases the diagnosis was made in individuals who reported a prior posi-
tive HIV test (i.e. known HIV infected). thirty-one percent of the individuals diagnosed 
with gonorrhoea were never tested for HIV before and 53% had a prior negative HIV test 
result (Appendix table A.17). the reported median number of partners was three for 
individuals diagnosed with gonorrhoea and three for gonorrhoea negatives (p<0.001). 
No differences were found between gonorrhoea positives and negatives in condom use 
during last sex contact. Gonorrhoea positives reported more often sexual contacts abroad 
than gonorrhoea negatives (11% vs. 8%, p<0.05). Most reported countries of contact were 
thailand, Spain and turkey.
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Figure 3.7: Number of gonorrhoea tests (left axis) and positivity rates (right axis) by   
gender/sexual preference, STI surveillance network, the Netherlands  2004 - 2007
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Co-infections
Of the reported gonorrhoea cases, 29% also had an infection with chlamydia and 4% had 
a syphilis co-infection. two percent of the cases had a new HIV infection. A history of 
gonorrhoea, infectious syphilis or genital chlamydial infection was reported by 36% of 
the men with gonorrhoea and by 25% of the women (Appendix table A.18, NA Amster-
dam). 
antimicrobial resistance of gonococci in the Netherlands3.2.3 
Complete data on the number of diagnosis and results of antimicrobial susceptibility 
testing for 2002-2006 were provided by 23 laboratories. A remarkable increase in resistance 
to quinolones (recommended first line therapy until September 20032) was observed: from 
6.6% (2002) to 26.4% in 2005 23, up to 38.0% in 2006 (Figure 3.8). resistance to cephalosporins, 
current first line therapy, has not yet been confirmed. the results of 2007 were not yet 
available at the time of writing and are expected at the end of 2008.
Gonococcal resistance to antimicrobials surveillance
In June 2006, the Gonococcal resistance to Antimicrobials Surveillance programme 
(GrAS) was implemented in the first StI clinic and at the end of 2007, GrAS was imple-
mented in seven regional StI clinics (in 14 of 34 StI centres in the national surveillance). 
In participating StI clinics, positive isolates of gonorrhoea were cultured again to test 
antimicrobial susceptibility. In 2006-2007, a total of 1,119 isolates were tested (2006: 177, 
2007: 942). resistance to ciprofloxacin  was 42%, resistance to tetracycline was 30% and 
penicillin resistance was found in 15% of all isolates tested. resistance to cephalosporins 
was not found (Figure 3.9). 
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Figure 3.8: Gonococcal resistance in the Netherlands, proportion of resistant cases as reported by 
public health laboratories, 2002-2006
BACtErIAL StI
41
Ciprofloxacin resistance was higher in MSM (51%) compared to heterosexual men and 
women (30%, p<0.05). Ciprofloxacin resistance among heterosexuals differed with ethnicity 
and was highest in persons from Eastern Europe (77%, n=20). Among those, 56% reported 
commercial sex working in the last six months. Ciprofloxacin resistance was lowest in 
persons from Surinam and the Netherlands Antilles. 
discussion3.2.4 
Compared to genital chlamydial infection, gonorrhoea is an infection with a transmission 
pattern more concentrated among MSM and individuals with a history of StI. Positivity 
rates remained fairly stable since 2004 for heterosexual men and women, while in MSM 
there was a decrease from 11% in 2004 to 9% in 2007. 
In 2006, the percentage of ciprofloxacin resistance in gonococci, as studied in a survey 
among public health laboratories, had further increased to 38%. results from GrAS 
showed an overall prevalence of ciprofloxacin resistance of 42% in 2006-2007. the highest 
prevalence was found in MSM (52%) and in heterosexuals from Eastern Europe (77%) and 
resistance was low in persons from Surinam and the Netherlands Antilles. the increas-
ing trend is consistent with recent data on gonococcal quinolone resistance from other 
European countries and indicates a potential European and worldwide public health 
problem.3, 24-27 therefore, guidelines have been changed and most countries do no longer 
recommend the use of fluoroquinolones for the treatment of gonococcal infections.28-30 In 
2007, high-level resistance to azithromycin was reported for the first time in the united 
Kingdom.31 Azithromycin is a recommended therapy for chlamydial infections. It also has 
activity against Neisseria gonorrhoeae, but is not a recommended therapy. However, dual 
infections with both chlamydia and gonorrhoea  are common and there is a possibility 
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Figure 3.9: Prevalence of antimicrobial resistance to Neisseria gonorrhoeae, GRAS, the Nether-
lands 2006-2007
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that azithromycin is used in cases where only the chlamydial infection is diagnosed and 
the presence of gonococci is not recognized. Continuous monitoring of the emergence 
and spread of antibiotic resistance in Neisseria gonorrhoeae is needed to enable physicians 
and public health workers to evaluate prevention and control programs including treat-
ment regimens. therefore, gonococcal resistance will be included in the new ISIS-Ar, a 
laboratory surveillance system which will replace the previous general ISIS, with a focus 
on monitoring of antimicrobial resistance.
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Syphilis3.3 
key points3.3.1 
In 2007, 559 diagnoses of infectious syphilis were made in the national surveillance • 
StI centres in the Netherlands (men: 92%, women: 8%). 
As in 2006, diagnoses of syphilis decreased further with 13% between 2006 and 2007. • 
this is in contrast with the re-emerging of syphilis diagnoses from 2000 to 2004. 
Syphilis cases were concentrated in men who have sex with men. • 
HIV and syphilis co-infections were frequently seen.• 
Recent trends syphilis, 3.3.2 Treponema pallidum 
Infectious syphilis includes the earlier stages of syphilis infection: primary (lues I) and 
secondary syphilis (lues II), and early latent (<1 year) stages or Lues latens recens. In 2007, 
559 diagnoses of infectious syphilis were made in the regional StI centres (Appendix 
table 11a). Infectious or early syphilis represented 86% of all syphilis diagnoses (n=652) 
in 2007: 36% lues I (n=201), 31% lues II (n=175) and 33% lues latens recens (n=183), while 
late syphilis or lues latens tarda represented 10% (n=58) of the diagnoses (6% not speci-
fied). Of all visitors, 98% was tested for syphilis. the positivity rate was 0.9%.
Gender, sexual preference and age groups of infectious syphilis
Men accounted for 92% of all infectious cases in 2007. the distribution of cases of infec-
tious syphilis was 1:12 in women versus men (42 versus 517 cases). the majority of cases 
were reported in MSM (463 cases, 90% of cases reported in men, and 83% of all cases). the 
Figure 3.10: Positivity rate of infectious syphilis by age and gender/sexual preference, STI surveil-
lance network, the Netherlands, 2007
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positivity rate of infectious syphilis was much higher in MSM (4.3%) than in heterosexual 
men (0.2%) and women (0.1%). 
the age distribution for infectious syphilis is rather different from that for other bacte-
rial StI. In men 50% and in women 33% of the cases were seen in the group above 40 
years old, although people in this age group are less frequent visitors of the StI centres. 
Syphilis positivity rates clearly increase with age (see Figure 3.10), although in MSM the 
rate decreases after the age of 55 years. the difference in positivity rate between hetero-
sexual men and women and MSM is very obvious throughout the different age groups. 
the positivity rate among young heterosexuals (under 25 years) was very low; for persons 
in this age group without any other indication of high-risk (see Methodology 1.1), only 
one positive syphilis case was reported32.
Regional pattern
the syphilis positivity rate by StI centre ranges from 0.3% to 1.3% (Figure 3.11). 
Trends in time
In 2007, more StI clinic attendees were tested on syphilis than the previous years (Figure 
3.12). However, the positivity rate decreased further in 2007, mainly due to a decrease 
in the cases seen in MSM. In heterosexuals the male to female ratio changed from 0.8 to 
1 in 2000 till 1.4 to 1 in 2007.
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Figure 3.11: Positivity rates of infectious syphilis by region, national surveillance STI centres, the 
Netherlands, 2007
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Syphilis screening of blood donors
In the Netherlands, blood donors are screened for syphilis. People who report specific 
risk factors for blood transmissible infections (such as HIV, HBV, HCV) are not accepted 
tot donate blood products. In 2007, in the total group of screened volunteers, 24 syphilis 
infections were found, 15 in regular donors and 9 in new donors. the overall incidence 
of syphilis among regular donors has increased from 2000 to 2005, decreased in 2006 
and shows again an increase in 2007 (4.0 per 100,000 donor years, Figure 3.13)
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Figure 3.12: Number of syphilis tests by gender and sexual preference, STI surveillance network, 
the Netherlands 2004-2007
Figure 3.13: Syphilis incidence (per 100,000 donor years) among regular blood donors in the 
Netherlands
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Risk groups 
MSM have the highest burden of syphilis, with 83% of all cases being diagnosed in MSM. 
For women, 29% of the syphilis cases were diagnosed in CSW (Appendix table A.15b). In 
heterosexual men, 17% of the infections were diagnosed in men who had recent (past 
six months) contact with CSW.
In men, 75% of the syphilis cases were Dutch, in women 48% were Dutch (Appendix table 
A.13a-b). the positivity rate was higher among MSM from Morocco and Northern Africa 
(7.8%), from the Netherlands Antilles (7.0%) and from Surinam (6.4%), compared to Dutch 
MSM (4.0%). In heterosexuals, numbers are to small to conclude on ethnic risk groups.
Co-infections
thirty seven percent of cases (n=210) diagnosed with infectious syphilis were HIV-positive. 
Of those, 173 (82%) were individuals who reported a prior positive HIV test (168 were MSM). 
the remaining 37, of whom 35 among MSM, were newly diagnosed HIV-infections, repre-
senting 12% of all new HIV-infections reported in the StI surveillance system in 2007. 
Fourteen percent of syphilis cases were also diagnosed with chlamydia and 10% with 
gonorrhoea. A history of infectious syphilis, gonorrhoea or genital chlamydia infection 
was reported by 32% of the individuals diagnosed with syphilis: 34% for men and 10% for 
women (see Appendix table A.18a-b, NA Amsterdam).
discussion 3.3.3 
the previous rise of syphilis cases reported in the Netherlands seems to have attenuated 
further in 2007. Syphilis was tested in the major part of visitors in the StI centres; tests 
were found to be positive in 0.9% of the clinic attendees. Cases were concentrated in MSM, 
of whom one in three reported a prior HIV infection. Co-infections were often diagnosed 
among persons with infectious syphilis and one in three reported a history of StI. Positiv-
ity rates were higher in MSM from specific migrant groups. Apart from (older) MSM, the 
visitors at highest risk were CSW. the chance to be diagnosed with syphilis increased 
with age in all groups. the proportion of women diagnosed with infectious syphilis in 
the StI surveillance system was relatively low. 
Notwithstanding decreasing positivity rates among heterosexual StI clinic attendees in the 
Netherlands, outbreaks of syphilis cases among heterosexuals have been reported in the last 
years.33-36 However, the main (social) determinants for syphilis transmission in developed 
countries remain (1) men having sex with men and (2) low socioeconomic status.37 
Next to routine testing for syphilis in the StI clinics, it may be worthwhile to concentrate 
further on case finding in specific risk-groups. the need to test routinely for syphilis in 
all young heterosexuals might need to be reconsidered. the StI clinic of Amsterdam and 
rotterdam and the Schorer Foundation, have started an internet project in November 
2007 to facilitate StI testing, focused on MSM (www.mantotman.nl). this projects aims 
at reducing the threshold for MSM to get tested for HIV and StI
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VIRaL StI4 
HIV and aIdS4.1 
key points4.1.1 
In 2007, 306 individuals were newly diagnosed with HIV at the StI centres, • 
235 HIV infections were diagnosed in MSM, accounting for 90% of the cases in men.• 
HIV positivity rates at StI centres in 2007 were 2.8 % (MSM), 0.1% (heterosexual men) • 
and 0.1% (women).
Of StI clinic attendees who were known HIV positive, 45% were diagnosed with a • 
concurrent StI. 
In 2007, 864 newly diagnosed HIV patients were reported in the national registration • 
of HIV treatment centres (source: HMF). 
the proportion of MSM accounting for new HIV cases reporting into care, increased • 
the last four years, up to 65% in 2007. the proportion of heterosexuals decreased 
(2007: 28%). 
A cumulative total of 14019 HIV patients, 7,515 AIDS cases and 4,661 deaths among • 
HIV patients in care were reported up to December 2007. 
StI centres 4.1.2 
Of all StI clinic attendees, 65,945 were tested on HIV antibodies. the proportion of StI 
clinic attendees that were tested on HIV has significantly increased from 56% in 2004 to 
86% in 2007 (p<0.0001). Of all attendees, 50% had no prior HIV test (women: 53%, men: 
47%). In 2007, 306 individuals were newly diagnosed with HIV (262 men and 44 women). 
Seventy-six percent (n=235) of all HIV infections were diagnosed among MSM. Among 
men, 52% were aged 25-39 years. Most diagnoses in women were made among women 
aged 20-34 years (59%) (Appendix table A.12b).
Of the new HIV diagnoses in men, 90% were seen in MSM (Appendix table A.14). Of all HIV 
infections in men, 68% were diagnosed in Dutch men, 5% in men from sub-Saharan Africa, 
and 7% in men from Surinam, the Netherlands Antilles and Aruba. In women, 18% were 
Dutch, 55% from sub-Saharan Africa and 16% in women from Surinam, the Netherlands 
Antilles and Aruba (Appendix table A.13). 
thirty-three percent (n=101) of all HIV infections were found among individuals who 
were never tested for HIV before, 62% had a prior negative HIV test. (Appendix table 
A.17). A history of StI (gonorrhoea, chlamydia or syphilis) was reported by 39% of the 
men with HIV and 13% of the women with HIV (Appendix table A.18, NA Amsterdam). 
Compared to 2006, the overall rate of positive HIV test results remained stable (2007: 
1.7%, 2006: 1.6%). 
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HIV positivity rates were higher in MSM (2.8%) than in heterosexual men (0.1%) and women 
(0.1%). the highest rate was found in MSM aged 35-39 (4.1%; Appendix table A.19). the 
positivity rate in MSM decreased over time (2005: 5.0%, 2006: 3.1%, 2007 2.8%). In hetero-
sexuals it did not change significantly over the last four years (Figure 4.1).
Among the StI clinic attendees, 1.9% had a prior positive HIV test (n=1,470); of whom 
98% were men (n=1,441) and 2% women (n=29). Of the 11,048 MSM clinic attendees, 1384 
(12.5%) were known HIV positive.
Concurrent STI
A concurrent StI was diagnosed in 45% of known HIV positive MSM, in 23% (n=12) of 
heterosexual male HIV positives and in 24% (n=7) of female HIV positives. In addition, 
in 101 of MSM clinic attendees a simultaneous new HIV-infection and a concurrent StI 
were diagnosed. Infectious syphilis, gonorrhoea and chlamydia were the most frequently 
diagnosed concurrent StI (see table 4.1).
Table 4.1: Concurrent STI diagnosed in known HIV infected individuals in 2007 (% of total known 
HIV infected individuals, N=1465*)
Diagnosis MSM (%)
N=1384
Heterosexual 
men (%)
N=52 
Women (%)
N=29
total (%)
N=1465
Gonorrhoea
Chlamydia
Infectious syphilis 
Genital warts 
Genital herpes
Concurrent StI**
258 (19)
257 (19)
168 (12)
77 (6)
54 (4)
622 (45%)
4 (8)
1 (2)
4 (8)
2 (4)
4 (8)
12 (23%)
1 (4)
2 (7)
0 (0)
2 (7)
2 (7)
7 (24%)
263 (18)
260 (18)
172 (12)
81 (6)
60 (4)
641 (43%)
* 5 clinic attendees did not report their sexual preference
** At least one concurrent StI diagnosed
0 
0,5 
1 
1,5 
2 
2,5 
3 
3,5 
4 
4,5 
5 
0 
5000 
10000 
15000 
20000 
25000 
30000 
35000 
2004 2005 2006 2007 2004 2005 2006 2007 
number of tests % pos
number of tests women number of tests men heterosexual number of tests MSM 
women % pos men heterosexual % pos MSM % pos
Figure 4.1: Number of HIV tests (left axis) and positivity rates (right axis) by gender/sexual pref-
erence, national STI surveillance network, the Netherlands, 2004 - 2007
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Behavioural indicators among HIV positive
HIV positive StI clinic attendees reported a higher median number of partners compared 
to other attendees (3 versus 2, NS). they reported equal condom use at last sexual contact, 
30% compared to others 29% (NS). Of them, 13% reported sexual contacts abroad in the 
previous three months and 17% reported a former StI.
Comparison between StI centres and other test sites4.1.3 
table 4.2 shows trends in HIV positive test results obtained from surveys at StI clinics 
in Amsterdam and rotterdam, the StI sentinel surveillance network and Checkpoint, a 
one-hour HIV testing facility in Amsterdam that started in 2002 and focuses on MSM 38 
(www.hivnet.org ). 
Among MSM, HIV prevalence rates varied between 2.8-21.9%. HIV prevalence in the 
anonymous surveys was higher than that in regular HIV tests by name. Anonymous HIV 
surveys are done in Amsterdam and rotterdam on all visitors, including people who are 
not tested during the regular consultation (because of opting-out or provider initiated 
if hiv positivity is known). Overall, these surveys showed a very high prevalence rate 
compared to the other data sources. However, this is due to the fact that a large propor-
tion of those not tested in the regular consultations, is already known HIV-positive. If we 
limit this analysis to people with unknown HIV-status tested anonymously, the positiv-
ity rates are much lower: 1.9% in MSM and 0.4% in heterosexual men and 0% in women 
(Amsterdam) and 12.5% in MSM and 0% in heterosexual men and women (rotterdam). 
Due to small numbers (e.g. in rotterdam the number of MSM tested this way was 24, of 
whom 3 were positive) the anonymous data may not add much to what is already known 
from the regular surveillance. 
In the anonymous surveys among MSM in Amsterdam, an increase of HIV prevalence was 
observed over time. the increase, however, is mainly caused by an increase in known HIV 
positive MSM attending the StI clinic: 93% of men in the anonymous survey knew their 
HIV status in 2007, compared to 80% in 2006, and 72% in 2004.39 
the HIV positivity among MSM in regular tests decreased slightly. At Checkpoint, the 
HIV prevalence among MSM was 2.8% in 2007, which is comparable with the prevalence 
at the regular screening at the StI clinic in Amsterdam and rotterdam (3.5% and 3.0%, 
respectively). HIV prevalence among heterosexual visitors of StI clinics and other test 
sites were stable and low over time. 
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Table 4.2: HIV prevalence among STI clinic attendees and other test sites [update anonieme 
screening a’dam komt volgende week]
region and source 2000 2001 2002 2003 2004 2005 2006 2007
MSM
StI clinic amsterdam
- regular
- Anonymous*
5.7%
16.9%
4.7%
14.6%
3.8%
20.3%
4.2%
20.1%
5.7%
18.8%#
6.0%
19.4%
4.0%
21.5%
3.5%
21.9%
StI clinic Rotterdam
- regular
- Anonymous*
1.6%
10.8%
2.9%
12.0%
6.2 %
13.4 %
1.7%
22.4 %
4.5%
32.1%
6.3%
25.7%
3.6%
38.5%
3.0%
58.4%
StI (sentinel) 
surveillance network
- - - 3.3% 4.2% 5.0% 3.1% 2.8%
Checkpoint - - 6.8% 4.8% 4.6% 5.7% 6.5% 2.8%
Heterosexual risk groups
StI clinic amsterdam
- regular, men
- Anonymous, men*
- regular, women
- Anonymous, women*
0.3%
0.9%
0.2%
0.6%
0.6%
0.4%
0.3%
0.3%
0.5%
0.4%
0.4%
0.8%
0.3%
1.0%
0.3%
0.5%
0.2%
0.5%#
0.3%
0.2%#
0.3%
0.0%
0.4%
0.4%
0.3%
0.4%
0.2%
0.4%
0.2%
0.3%
StI clinic Rotterdam
- regular, men
- Anonymous, men*
- regular, women
- Anonymous, women*
0.7%
0.2%
0.2%
0.3%
0.4%
0.8%
0.4%
0.8%
0.3%
0.5%
0.3%
0.9%
0.5%
1.0%
0.3%
1.0%
1.0%
0.9%
0.3%
0.7%
0.3%
0.4%
0.2%
0.5%
0.2%
0.5%
0.2%
0.2%
0.1%
0.6%
0.1%
2.8%
StI (sentinel) 
surveillance network
- Men
- Women
-
-
-
-
-
-
0.3%
0.3%
0.3%
0.2%
0.3%
0.2%
0.2%
0.1%
0.1%
0.1%
Checkpoint
- Men
- Women
-
-
-
-
0.8%
1.1%
0.3%
1.0%
0.4%
0.5%
0.7%
0.0%
1.2%
0.0%
0.0%
1.0%
* Known HIV infected included, # based on 1 research period
HIV treatment centres 4.1.4 
By the end of 2007, a cumulative total of 14,019 HIV patients with a known year of diag-
nosis had been registered by HIV treatment centres in the national database of the HIV 
Monitoring Foundation (HMF) [www.hiv-monitoring.nl]. For 162 other cases the year of 
diagnosis was unknown (excluded from the analysis). (Figure 4.2)
In the registration, so far 864 new cases of HIV diagnosed in 2007 are included, but it is 
expected that more people will still be included with an initial diagnosis in 2007. Of all 
registered cases, 10,897 (78%) were men and 3,122 (22%) were women. Of all individuals, 
98.8% were infected with HIV-1, 0.6% with HIV-2 and 0.6% with HIV-1 and HIV-2. 
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Footnote: only HIV patients with a known date of diagnosis are included (AtHENA: 1996-2001, 
national registration from 2002 to date 
Figure 4.2: Number of HIV cases (right axis: cumulative), by year of HIV diagnosis 
New registered HIV diagnoses in care in 2007 
Of the 864 new HIV cases reported in 2007 in the national registration of HIV treatment 
centres, 711 (82%) were male and 153 (18%) were female. Of the new cases, 93% were 
infected sexually: 28% through heterosexual contact and 65% through MSM. Of all men, 
79% acquired the infection through sex with men. Of all women, 92% acquired the infec-
tion through heterosexual contact. Of all heterosexual cases, 57% were female. 
Injecting drug use accounted for 0.6% (n=5) of the new diagnoses and risk through blood 
(products) for 0.2% (n=2). For 6%, the transmission route was undetermined (Appendix 
table B.12).
Of the cases, 64% came from the Netherlands, 14% from sub-Saharan Africa, 10% from 
Latin America and the Caribbean (Appendix table B.13).  the median age at diagnosis in 
2007 was 39 years and differed per risk group: the median age in MSM was 39 years, in 
heterosexuals 38 years and in IDus 47 years (Appendix table B.16). Eight cases (1%) were 
identified among young people (0-19 years).
Focus on risk groups in all registered HIV cases in care
From 2004, the annual number of new HIV diagnoses among MSM in the national HIV 
registry increased up to 579 in 2006. In 2007, 561 HIV diagnoses among MSM were 
recorded, but this number may further increase due to the reporting delay. the total 
number of registered HIV diagnoses among heterosexual men increased slightly between 
2000 and 2005. the number of heterosexual HIV infected women decreased after 2002 
(2007 still incomplete).
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Less than 5% of the total HIV infections were among IDus. Mother-to-child transmission 
and transmission through blood (products) both accounted for 1% of the all registered 
infections (Appendix table B.2). In 7% of the HIV diagnoses the transmission risk group 
was unknown.  
the relative contribution of each risk group to the annual number of diagnoses changed 
over time (Figure 4.3). the proportion of MSM declined from 57% of the new diagnoses 
in 1996 to 45% in 2001-2003, and increased thereafter to 65% in 2007. the proportion of 
heterosexuals increased from 25% in 1996 to 44% in 2000-2003, and declined again to 
28% in 2007 (p< 0.0001).  
Young people
Of all registered HIV cases, 192 were children between 0-14 years at diagnosis (1%), 358 
(3%) were teenagers between 15-19 years at diagnosis, 1,265 (9%) were young adults 
(20-24 years) and 2,305 (16%) were individuals aged 25-29 years at diagnosis (Appendix 
table B.5). 
Fifty-eight percent of the children <15 years were Dutch and 30% were from sub-Saharan 
Africa. Of teenagers aged 15-19, 54% were from sub-Saharan Africa and 22% from the 
Netherlands. young adults (20-29 years) were from the Netherlands (39%), sub-Saharan 
Africa (29%) and Latin America/Caribbean (14%). 
Men who have sex with men 
the majority of HIV infected MSM was Dutch (73%) (Appendix table B.4). the absolute 
number of Dutch MSM increased after 1999 from 235 to 438 in 2007. the number of MSM 
from other countries remained fairly stable over time (Figure 4.4). For 73% of the MSM, 
the country of infection was known. the majority of the MSM (89%) were infected in the 
Netherlands; 96% among Dutch MSM and 61% among non-Dutch.
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Figure 4.3: Proportion of annual HIV cases in care per transmission risk group, by year of diagno-
sis, 1996-2007 (Source: HMF)
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MSM were, on average, younger at HIV diagnosis than heterosexual men. Over time, age 
at HIV diagnosis has increased considerably. For Dutch MSM, the age increased from 32 
in 1987 to 39 years in 2007. For non-Dutch MSM, the age increased from 28 in 1987 to 
37 in 2007 (Appendix figure B.3).
Migrant populations
Of all registered HIV patients, 44% were born abroad. the majority (40%) of the migrants 
originated from sub-Saharan Africa, 25% from Latin America/Caribbean, 15% from Western 
Europe and 7% from South (East) Asia. Figure 4.5 shows the distribution of transmission 
risk groups among HIV patients for different regions of origin. the largest risk group 
among the Dutch population was MSM (69%), while MSM only accounted for 4% of the 
infections among sub-Saharan Africans (SSA). the proportions of MSM among individuals 
from Surinam and the Netherlands Antilles were 34% and 39%, respectively.
Eighty-eight percent of the individuals from sub-Saharan Africa, for whom the country of 
infection is known (69%), were infected in SSA. Among Surinamese individuals (country 
of infection known: 61%), only 22% were infected in Surinam and 76% in the Netherlands. 
twenty nine percent of the individuals from the Netherlands Antilles/Aruba were infected 
in their region of origin. Most people from turkey and Morocco reported to be infected 
in the Netherlands. 
For HIV patients from Surinam or the Netherlands Antilles, the country of infection 
differed between risk groups: MSM from Surinam or the Antilles and heterosexuals from 
Surinam more often acquired the infection in the Netherlands; whereas heterosexuals 
from the Antilles and Aruba more often became infected in the country of origin.
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Figure 4.4: Reported country of infection of MSM, by year of diagnosis, 1996-2007 (Source:HMF) 
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Age at diagnosis
Among heterosexual women, African women were the youngest at diagnosis (median 
age: 29.2 years). Dutch and West European women were the oldest: 33 years. Among 
heterosexual men, Asian men were the oldest (41 years), and African the youngest 
(34 years).
MSM IDU blood products MTCT Other/unknownheterosexual
Netherlands Surinam
Netherlands Antilles
SSA
Figure 4.5: HIV infected individuals, by transmission risk group and region of origin, hiv-register 
2007 (Source: HMF)
Footnote MtCt: mother to child transmission; IDu: injecting drug use; MSM: men having sex 
with men
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Figure 4.6: Reported country of infection of heterosexuals, by year of diagnosis, HIV register 2006 
(Source: HMF) 
* 2007 data still incomplete
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the median age at diagnosis showed a slightly increasing trend over time for heterosexu-
als from sub-Saharan Africa, Latin America/Caribbean and the Netherlands (Appendix 
figure B.2). Heterosexuals of African origin are the youngest at HIV diagnosis (33 years). 
Heterosexuals from Latin America or the Caribbean who were diagnosed in 2007 had a 
median age of 43 years and were slightly older than the Dutch heterosexuals (41 years). 
the median age of MSM clearly increased over time, from 32 years in 1987 to 40 years in 
2007 for Dutch men and from 28 years to 37 years in 2007 for non-Dutch MSM (Appendix 
figure B.3).
Geographical differences
Forty two percent of all HIV infected individuals were seen in treatment centres in 
Amsterdam (table B.1). Prevalence of HIV infections per 100,000 inhabitants in 2007 are 
shown for each province in Figure 4.7. the province of ‘Noord-Holland’ has the highest 
HIV prevalence (12.6/100000), followed by the provinces utrecht (6.8/100000), Gronin-
gen (6.4/100000) and ‘Zuid-Holland’ (5.1/100000). the number of new HIV diagnoses in 
Amsterdam remained fairly stable between 340 and 390 per year in the past eight years. 
the number of HIV diagnoses outside Amsterdam increased between 2000 and 2005 (in 
particular in utrecht and rotterdam) but seems to have levelled off in 2006 and 2007. 
Figure 4.7: Number of new HIV diagnoses in 2007 per 100,000 inhabitants; calculations based on 
HIV infections recorded in the various HIV treatment centres in each province (Source: HMF)  
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aIdS cases and deaths among HIV patients4.1.5 
By the end of 2007, a cumulative total of 7515 AIDS cases was registered in the Netherlands 
(Appendix table B.18-19). the number of new AIDS cases peaked in 1995, and declined 
sharply over the subsequent four years, as the result of the introduction of HAArt. Since 
1999, the rate of decline had slowed and decreased even further after 2005.
the  proportion of MSM among reported AIDS cases increased from 39% in 2004 to 50% 
in 2007. Conversely, the proportion of AIDS cases among heterosexuals decreased from 
39% in 2004 to 37% in 2007. the median age at AIDS diagnosis in 2007 was 43 years; men 
were older than women, respectively 43 and 37 years. On average, Dutch individuals were 
older at AIDS diagnosis than individuals of African origin: 44 and 37 years (Appendix 
table B.20).
the number of deaths among HIV patients showed a similar trend. Between 1983 and 
2007, a cumulative total of 4,661 HIV infected individuals were known to have died of 
which 116 died in 2007. HAArt had a major effect on the number of deaths and, as a 
consequence, the number of people living with HIV increased. the registered number 
of HIV- patients alive is over 12,500.  
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  Footnoe: the low value in 1999 is caused by the change in data sources of AIDS cases (sources AIDS 
cases: AIDS registration Health Inspectorate <1999, HMF ≥1999. Sources deaths: CBS <2002, HMF 
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Figure 4.8: Number of AIDS cases and deaths among HIV patients (Source:HMF) 
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Nationwide HIV screening4.1.6 
Blood donors
In the Netherlands, blood donors are screened for HIV antibodies since 1985. People who 
report specific risk factors for blood transmissible infections (such as HIV, HBV and HCV) 
are not accepted. In 2007, in the total group of screened volunteers, six HIV infections 
were found, three in repeat donors and three in new donors. the overall prevalence 
among new donors increased to 11.0 per 100,000 donors, the incidence among regular 
donors remained low: 1.0 per 100,000 donor years (Figure 4.9 and Figure 4.10). 
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Figure 4.9: HIV prevalence (per 100,000 donors) among new blood donors in the Netherlands 
(Source: Stichting Sanquin Bloedvoorziening, Amsterdam)
Figure 4.10: HIV incidence (per 100,000 donor years) among regular blood donors in the Nether-
lands (Source Stichting Sanquin Bloedvoorziening, Amsterdam)
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Pregnant women 
In 2006, 14385 women were offered an HIV test in Amsterdam (4 persons refused). the 
total HIV prevalence was 0.17% (24/14381). Of these 24 women, 21 knew their HIV posi-
tive status and 22 had a non-Dutch origin (15 sub-Saharan Africa, 5 Surinam/Antilles, and 
1 Belgium).40 At the time of writing, data of 2007 were not available yet.
Since 1988, pregnant women in Amsterdam are tested for HIV in a sentinel surveillance 
study.40 until 2002, HIV prevalence was slightly increasing; the last few years mainly due 
to an increase of known HIV positive women becoming pregnant (Figure 4.11). In 2006 
HIV prevalence in this sentinel surveillance was 1.4% (22/1,541) which is comparable to 
2005 (1.5% 26/1,701). 
HIV incidence in the amsterdam Cohort Studies (aCS)4.1.7 
MSM
the HIV incidence among MSM in the ACS in 2007 was estimated at 1.22 per 100 person-
years (Py). the last decade, the HIV incidence is relatively stable in the range of 0-2 per 
100 Py, see Figure 4.12 (www.amsterdamcohortstudies.org). 
Drug users
the first enrolment of IDus in the ACS took place between 1985 and 1990. From 1998, 
recruitment was focused on young drug users (≤30 years). No HIV infections were found 
among IDus from 1999 until 2004, in 2005 two IDus were tested positive (incidence 0.85 
per 100 Py). In 2006 and 2007, no HIV infections were found among non-injecting and 
injecting drug users, see Figure 4.13 (www.amsterdamcohortstudies.org).
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Figure 4.11: HIV prevalence (%) and number of tests among pregnant women in Amsterdam 
(sentinel study)
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 discussion 4.1.8 
In 2007, 306 new HIV diagnoses were recorded in StI centres (1.7% positivity rate among 
those not yet known to be HIV positive) which is comparable to 2006. It is not yet clear if 
this stabilisation will also be reflected in the total number of new HIV patients in care in 
2007, as registration data of all HIV patients in care by year of diagnosis have a considerable 
lag time prior to being complete. So far 864 new HIV diagnoses were reported in 2007. 
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Figure 4.12: Yearly HIV incidence among MSM in Amsterdam Cohort Studies (Source Overview of 
the Amsterdam Cohort Studies among homosexual men and drug users, Health Service, Amster-
dam, May  2008 (www.amsterdamcohortstudies.org
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Figure 4.13: Yearly HIV incidence among IDUs (30 years or younger at entry) in Amsterdam 
Cohort Studies (Source Overview of the Amsterdam Cohort Studies among homosexual men and 
drug users, Health Service, Amsterdam, May 2008 (www.amsterdamcohortstudies.org)
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In 2007, the proportion of StI clinic attendees tested for HIV in the national registration of 
StI centres, increased further to 86%, enhanced by the introduction of ‘opting-out’ testing 
procedures in some of the StI clinics. In total, 306 individuals were newly diagnosed with 
HIV, the majority in MSM (77%). the HIV positivity rate among both MSM and heterosexuals 
has attenuated further in 2007. In HIV cases reported in care, the increase of the propor-
tion MSM continued in 2007, while the proportion of heterosexuals further decreased. 
Sixty-five percent of the HIV infections were diagnosed in MSM, who were mainly Dutch. 
the majority also acquired their HIV infection in the Netherlands. In contrast to the MSM 
population, the majority of the heterosexuals acquired the HIV infection abroad; in sub-
Saharan Africa and to a lesser extent in Latin America and the Caribbean. Migration thus 
still plays an important but decreasing role in the Dutch HIV epidemic.
the high uptake of testing with the introduction of an opting-out system, guarantees a 
valuable insight in the prevalence of HIV among the clinic attendees. With such a high 
uptake, the additional value of anonymous testing needs careful evaluation, in particular 
because the additional tests in the past included a relatively large number of HIV tests 
in known HIV-positive people.
the evaluation of the anonymous unlinked HIV surveys in 2007 among IDu, CSW and 
migrants from HIV-endemic countries, emphasized the need to investigate further exist-
ing routine data sources on risk groups. In 2008, the possibility of collecting data from 
infectious disease screening of drug users in health care is being explored. We expect to 
collect data on a regular basis from this screening in 2009. In addition, data on ethnicity 
from the national HIV screening among pregnant women will contribute to the insight 
in the HIV (as well as syphilis and hepatitis B) epidemiology in the general heterosexual 
population. 
Concurrent StI were diagnosed in 43% of known HIV infected who were consulting a 
StI centre, especially among MSM (45%), facilitating HIV transmission. this indicates 
continuing extremely high risk behaviour in this group. In 2008, a pilot project for StI 
screening of HIV positive MSM (and heterosexuals) in care has started in Amsterdam 
and rotterdam.  
One of the constraints of the current StI and HIV/AIDS surveillance system is that most 
data do not represent recent HIV infections, apart from the ACS and one study among 
MSM in Amsterdam. In 2006, a research collaboration started between EuroHIV, the 
Health Protection Agency in London and six countries including the Netherlands (rIVM 
and GGD Amsterdam) in which various assays for the detection of recent HIV infections 
are being validated. the first results of this study are reported to the ECDC. results for 
the Netherlands will be described in a separate publication. this study might provide 
more insight in recent and prevalent infections among newly diagnosed HIV infected 
MSM in Amsterdam. Furthermore, insight into newly acquired HIV infections will provide 
valuable information on the course of the HIV epidemic and is helpful in monitoring the 
effect of changes in risk behaviour and prevention activities. 
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to get more understanding of the number of HIV-positive people diagnosed and undi-
agnosed, the national estimate of 18,500 people living with HIV/AIDS in the Netherlands 
will be updated in 2008. 
In 2008, we will start a new collaboration with the HMF and StI centres to study the time-
interval between a positive HIV test and the start of HIV treatment. By using modelling, 
virological and behavioural data, we will study the frequency, prevalence and potential 
impact of a delayed treatment on HIV transmission in the Netherlands. 
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Hepatitis b4.2 
key points4.2.1 
In 2007, the incidence of notified cases of acute HBV was 1.3 per 100,000 inhabitants • 
and was higher in men (2.1) than in women (0.6).
unprotected sexual contact was the most important risk factor for acute hepatitis B.• 
the number of acute HBV notifications decreased with 9% compared to 2006.• 
Genotype A was most common in the Netherlands in acute HBV patients. • 
Recent trends hepatitis b4.2.2 
In 2007, 220 cases of acute hepatitis B were diagnosed in the Netherlands, 168 men 
(76%) and 52 women (24%), a decrease of 9% compared to 2006 (2006: 242 cases, 2005: 
302 cases).41
Gender, sexual preference and age group
the incidence rate for acute HBV in 2006 was 1.3 per 100,000 and was higher in men 
(2.1) than in women (0.6) (Figure 4.14). the median age at diagnosis for men was 41 
years (range: 2-75) and was significantly higher (p<0.05) than for women 29 years (range: 
15-91). Incidence in men was highest in 30-34 year old men (4.3 per 100,000), in women 
incidence was highest in the age group of 20-24 years (2.5 per 100,000).
Sexual contacts, heterosexual as well as homo- or bisexual contacts, were the most 
reported routes of transmission (Figure 4.15). Since 2003, number of infections due to 
Figure 4.14: Incidence of acute HBV by gender, 1976-2006. (Source: RIVM-Osiris, notification 
data)
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MSM decreased with 25%. Since 2004, acute hepatitis B infections due to injecting drug 
use are very low in the Netherlands. 
At time of diagnosis, MSM were on average 8 years older than heterosexually infected 
persons (p=0.07, table 4.3).  Heterosexuals reported more often to be born abroad (p<0.05). 
Among MSM, 72% acquired the infection through a casual partner, among heterosexuals 
this was 54% (p<0.05). 
Table 4.3: Proportion of HBV cases by route of transmission (three most common routes), by 
sexual preference, the Netherlands, 2007 (Source: RIVM-Osiris, notification data)
MSM
(n=78)
Heterosexual contact 
(n=69)
total
(n=220)
N % N % N %
Infected abroad 11 14% 16 21% 38 17%
Born abroad 8 10% 19 28% 43 20%
Infected by casual partner 56 72% 37 54% 95 43%
Median age (+ range) 42 (12-63) 34 (15-81) 39 (2-91)
* NB: proportions per category can overlap, so percentages do not add up to 100%
Regional pattern 
the incidence of acute HBV is unevenly distributed across the Netherlands, (range: 
0.0 – 3.1 per 100,000), see Figure 4.16.
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Figure 4.15 Number of infections of acute HBV by route of transmission, 2003-2007. Source: 
RIVM-Osiris, notification data) 
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Risk groups
Of the acute HBV cases, 77% (n=170) was born in the Netherlands, 20% (n=43) was born 
abroad and in 3% the country of birth was unknown. Of the cases born abroad, 26% came 
from HBV high endemic regions (HBsAg prevalence ≥ 8%), 70% from intermediate endemic 
regions (HBsAg 2-7%) and 4% from low endemic regions (HBsAg ≤ 1%). Seventy-six percent 
of all acute HBV cases reported to be infected in the Netherlands, 17% reported an infec-
tion abroad and in 7% of the cases the country of infection was unknown. 
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Figure 4.16: Incidence of acute hepatitis B per 100,000 inhabitants by region, 2007 (Source: 
RIVM-Osiris, notification data)
Figure 4.17: HBV incidence (per 100,000 donor years) among regular blood donors in the Nether-
lands (blood donor register 1998-2007) 
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Blood donors 
In the Netherlands, blood donors are screened for HBV. People who report specific risk 
factors for blood transmissible infections are not accepted. In 2007, in the total group 
of screened volunteers, 19 HBV infections were found, four in regular donors and 15 in 
new donors. the overall incidence of HBV among regular donors decreased the last two 
years (2007: 1.1 per 100,000 donor years, Figure 4.17)
HbV in the national surveillance of StI centres4.2.3 
In 2007, 244 diagnoses of HBV were registered in the national StI surveillance network; 
21 of those (9%) were acute and 223 (91%) were chronic. Most patients were male (72%) 
and aged between 20-29 years (48%). In men, 72% of the diagnoses were made in hetero-
sexual men. 
About 27% of the diagnoses were made in Dutch individuals. Among migrant popula-
tions, most diagnoses were made in cases from Sub-Saharan Africa (21%), Surinam and 
the Antilles (11%) and Eastern Europe (9%). 
In addition, 1,914 individuals appeared to have markers of recovered HBV infection (NA 
Amsterdam). 
Vaccination policy of HbV4.2.4 
the Netherlands is a low endemic country with a higher prevalence of HBV in specific risk 
groups and import of infection. to increase HBV protection, a vaccination programme was 
started in 2002 targeted at MSM, hard drug users, sex workers, and heterosexuals with 
multiple sex partners, in addition to individuals working in medical professions, pregnant 
women, newborns with migrant parents (HBV highly endemic regions), and children with 
Down syndrome. the vaccination programme for behavioural risk groups is co-ordinated 
by the Netherlands Association for Community Health Services (GGD Nederland). 
From 2002 up to January 2008, approximately 82,000 persons received a first HBV vacci-
nation, 65,000 (79%) %also received a second one, and 49,000 (60%) persons were fully 
vaccinated.  Also, about 7400 (9%) persons appeared to be immune for an HBV infection 
and 563 (0.7%) persons were chronic carriers.42 
molecular epidemiology of acute HbV4.2.5 
In 2006, 220 acute cases were notified, and the genotypes of 100 have been determined 
up till now. As well as in previous years, genotype A was the most common genotype 
(63%), followed by genotype D (26%). the proportion of acute HBV cases with genotype 
A decreased in 2007 compared to 2006, while genotype D has increased compared to 
2006 (Figure 4.18). 
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Of all infections with genotype A in 2007, 44% were acquired by sexual contact between 
MSM and 30% by heterosexual contact. Between 2004-2007, the fraction of MSM within 
the identical genotype A cluster decreased from 61% in 2004 to 47% in 2007.
Within genotype D, most patients were infected by heterosexual contact (50%), comparable 
to previous years. Patients with genotype B, C, D en E reported more often to be infected 
abroad or via a partner from abroad compared to patients with genotype A. 
discussion4.2.6 
In 2007, the incidence of acute HBV in the Netherlands was 1.3 per 100,000, which is a 
decrease compared to the previous years. In men, the incidence decreased from 3.1 in 
2003-2004 to 2.1 in 2007, in women the incidence decreased slightly from 0.9 in 2003 to 
0.6 in 2007. Compared with 2003, the number of notifications of acute hepatitis B infec-
tion decreased with 33%, mainly due to a decrease in notified cases among MSM (-25%) 
and due to a decrease in notifications with an unknown route of transmission (-41%). 
Genotype A is still the most common genotype in the Netherlands (63%), mainly found 
in MSM (44%). the fraction MSM within the identical genotype A decreased between 
2004 and 2007, which indicates less sustained transmission. together with the decrease 
in number of notifications, this changing pattern of genotype is probably due to the 
vaccination campaign, targeted at high-risk groups, including MSM.
During an expert meeting in March 2007, evidence was reviewed to guide the future 
vaccination campaign. Main conclusions from this meeting were that MSM remain the 
most important high-risk group for HBV, whilst CSW and (injecting) hard drug users 
and heterosexuals contribute little to HBV transmission. the HBV vaccination campaign 
will be enhanced for MSM, continued for CSW and hard drug users and discontinued for 
heterosexual people with a high rate of partner change.43 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
2004 2005 2006 2007 
F E D C B A 
Figure 4.18. Genotype distribution of acute case of HBV infection, 2004-2007
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Hepatitis C4.3 
Compared to 2006, an increase of 60% was observed in the number of cases of acute 
hepatitis C (HCV) infections reported in 2007, which was due to a rise of cases among 
MSM (Figure 4.19). Of the 30 individuals who contracted HCV through sexual contact, 29 
were men having sex with men. Most infections were reported by public health services 
in Amsterdam and rotterdam. 
Age at diagnosis varied from 29 to 60 years. the majority of men originated from the 
Netherlands (69%) and the reported country of infection was also most frequently the 
Netherlands (73%). For 50% of the cases, no signs or symptoms of acute infection were 
reported. 
In the Netherlands, blood donors are screened for hepatitis C at each donation. In 2007, in 
the total group of screened volunteers, four HCV infections were found, one in a regular 
donor and three in new donors. the overall incidence of HCV among regular donors 
fluctuated the last years (2007: 0.3 per 100,000 donor years, Figure 4.20).
Figure 4.19 Number of infections of acute HBV by route of transmission, 2003-2007. Source: 
RIVM-Osiris, notification data) 
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Figure 4.20: HCV incidence (per 100,000 donor years) among regular blood donors in the Nether-
lands (blood donor register 1998-2007)
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genital warts4.4 
key points4.4.1 
In 2007, 2,061 diagnoses of genital warts were reported in the national surveillance • 
of StI centres (men: 60%, women: 40%).
Genital warts are the most prevalent viral StI reported in the Netherlands. Compared • 
to 2006, the number of diagnoses increased with 7%.
Recent trends genital warts4.4.2 
Genital warts, a viral StI caused by human papilloma virus, were the most frequently 
diagnosed viral StI in all StI centres. In 2007, 2,061 diagnoses of genital warts were made 
(1,233 in men and 828 in women). the number is probably higher, because reporting of 
genital warts is optional. Of all genital warts infections, 79% were diagnosed in Dutch 
men, 85% in Dutch women (Appendix table A.13a-b). 
Most diagnoses were made among men aged 20-29 years (46%) and among women 
aged 20-24 years (45%). In the older age groups the number of infections is lower. A 
co-infection with chlamydia was found in 10% of those being diagnosed with genital 
warts, a co-infection with gonorrhoea in 3% and syphilis in 2% and a co-infection with HIV 
in 0.6% (only in men). A history of gonorrhoea, infectious syphilis or chlamydial infection 
was reported for 15% of the women and for 8% of the men diagnosed with genital warts 
(Appendix table A.18 a/b, NA Amsterdam). 
Figure 4.21: Number of new cases of genital warts by gender and sexual preference, national STI 
surveillance network, the Netherlands, 2004-2007
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Compared to 2006, the registered number of diagnoses of genital warts has increased 
by 7% in 2007, both in men and in women.
discussion4.4.3 
Human papilloma viruses are the most common sexually transmitted viral agents. Genital 
warts, frequently caused by HPV type 6 or 11, are the most prevalent viral StI diagnosed in 
the Netherlands in 2007, Persistent HPV infection might eventually lead to cervical cancer. 
About 20 different genotypes are able to cause cervical cancer, and the most prominent, 
so-called High-risk genotypes are HPV-16 (app. 55% of cervical cancer cases), HPV-18 
(approximately 11%), HPV-45 (app. 4%) and HPV-31 (app. 3%). Effective HPV vaccines have 
been developed (Merck (Gardasil): HPV-6, -11, -16, -18 and GSK (Cervarix): HPV-16 and -18). 
In April 2008, the Dutch Health Council has advised the Ministry of Health, Welfare and 
Sports to include the HPV vaccine in the National Immunisation Programme for young 
girls (age before sexually active). For monitoring the effect of vaccination, standard record-
ing of genital warts in the SOAP registration of the StI centres, especially in younger age 
groups, with a distinction between new and recurrent infections, would be valuable. 
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genital herpes4.5 
key points4.5.1 
In 2007, 671 diagnoses of primary genital herpes were made in the national surveil-• 
lance of StI centres (men: 52%, women: 48%). 
Diagnoses of genital herpes increased with 13% compared to 2006.• 
37% of the diagnoses in men were made in MSM.• 
Recent trends genital herpes4.5.2 
In 2007, 671 diagnoses of primary genital herpes were made (347 in men and 324 in 
women) in all StI centres, representing 4% of all positive StI diagnoses. Of all diagnoses, 
HSV type 1 accounts for 41% (n=275), HSV type 2 for 50% (n=335) and HSV type 1 or 2 
for 6% (n=39). In addition, 27 patients with a recurrent genital herpes infection were 
diagnosed.
A co-infection with chlamydia was found in 7.5% of those being diagnosed with genital 
herpes, a co-infection with gonorrhoea in 3.4% and syphilis in 1.6% and a co-infection 
with HIV in 1.5%. A history of gonorrhoea, infectious syphilis or chlamydial infection was 
reported for 21% of the men and for 10% of the women diagnosed with genital herpes 
(Appendix table A.18 a/b, NA Amsterdam). 
Gender, sexual preference and age group
Among men, most diagnoses of genital herpes were made in men aged 25-29 years (19%); 
in women most diagnoses were made in women aged 20-24 years (38%). In the older age 
groups the number of infections is lower (table A.12). Of all diagnoses in men, 63% (n=219) 
were made in heterosexual men and 37% (n=127) in MSM (Appendix table A.14).
Trends in time 
From 2004-2007 there was an increase in primary herpes infections of 36%, mainly caused 
by an increase of herpes infections in women (79%). In heterosexual men the number of 
infections remains stable, and in MSM there was an increase of 51% between 2004 and 
2007 (Figure 4.22). 
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Risk groups
About 76% of the diagnoses in were made in Dutch men, 77% in Dutch women (Appendix 
table A.13). Among non-Dutch, the highest percentage of diagnosis was made in men and 
women from Surinam and the Netherlands Antilles (10% and 9% respectively).
In men, 6% of the infections were diagnosed in patients who had recent (past 6 months) 
contact with CSW, whereas for women 6% were diagnosed in CSW (Appendix table A.15). 
In 9% (n=60) of the cases of genital herpes the diagnosis was made in individuals who 
reported a prior positive HIV test (known HIV positives) 
discussion4.5.3 
Diagnoses of genital herpes, mainly caused by HSV-2, increased with 13% in 2007. At 
national population level, results from a seroprevalence study performed in 1995-1996 
showed an overall HSV-1 prevalence of 60%. For HSV-2, the overall prevalence was 8.4%.44 
In 2006, a new seroprevalence study has been performed in the Netherlands, but results 
are not available yet.
Vaccines against Herpes simplex virus are being developed. the National Institute of Health 
in the united States is currently in the midst of phase III trials of a vaccine against HSV-2, 
called Herpevac.45-47 the vaccine has only been shown to be effective for women who 
have never been exposed to HSV-1. Overall, the vaccine is approximately 48% effective 
in preventing HSV-2 seropositivity and about 78% effective in preventing symptomatic 
HSV-2. As vaccine development is still in a preliminary phase, it is too early to discuss 
availability in the Netherlands. 
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Figure 4.22: Number of new diagnoses of primary genital herpes infections by gender and sexual 
preference in the national STI surveillance network, 2004-2007
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FOCuS ON SpeCIFIC gROupS 5 
mSm5.1 
Men who have sex with men clearly are at higher risk of contracting an StI or HIV infec-
tion.  this group appears to be well reached by the low-threshold StI centres, based on 
the relatively high percentage of MSM seen in the centres (28% of men reported homo- 
or bisexual preference) compared to the general population (6-7%).48 However, to what 
extent the MSM visiting the StI centres accurately represent all MSM in the Netherlands, 
is not known. Probably the urban population is over-represented as 44% of MSM clinic 
attendees were seen in Amsterdam StI centre and an additional 20% in rotterdam, the 
Hague and utrecht. Nevertheless, proportions remained stable over the years; hence the 
primary objective of surveillance among high risk groups and valuable trend analysis 
can be achieved.
MSM remain the group at highest risk for acquiring and transmitting StI, including HIV, 
in 2007. Following dramatic increases in gonorrhoea and syphilis in the 1970’s and 1980’s 
and HIV in the 1990’s of the previous century, and smaller increases in the beginning of 
the new millennium, overall numbers have decreased considerably in the last couple of 
years. the decrease in posititivity rates for these three StIs is also obvious among MSM at 
the StI clinics, but rates are still 6, 10 and more than 25 times higher, respectively, than in 
heterosexual men. Positivity rates of all StIs increase with age among MSM, unlike those 
in heterosexual men and women. LGV cases are, since 2004, only diagnosed in MSM.  
the fraction of new HIV cases attributable to MSM at the HIV registry rose in the past 
years, confirming that this is the main population group where HIV transmission in the 
Netherlands occurs. At the same time, MSM who are aware of their HIV-positive status 
still practice very high-risk or unsafe sex, as seen by the alarmingly high percentage of 
co-infections: 45% of the known HIV- positive MSM and 43% of the new HIV-positives 
diagnosed in MSM attending an StI clinic had a concurrent StI diagnosed. Also this 
year a sudden increase in sexually transmitted acute Hepatitis C was seen in this specific 
group.
Chlamydia infections are equally common among heterosexuals and MSM, but the location 
of infection for MSM is anorectal in more than half of the cases (59%). LGV infections were 
all anorectal. the location of gonorrhoea infections in MSM was in 46% of cases anorectal 
and 18% oral. According to the behavioural surveillance data, 40% of MSM reported the 
use of condoms at their last sexual intercourse (NA Amsterdam and utrecht); this was not 
more frequent in known HIV-positive MSM (37%), but it was higher than the 32% reported 
for MSM in 2006 and higher than among heterosexual men (29%). No data are available on 
the consistency, adequacy and correct use of condoms or other StI-protection in different 
types of sexual activities.  the proportion with an StI (Chlamydia, Gonorrhoea, Syphilis, 
HBV or HIV) was higher in MSM reporting not to have used condoms (12% vs. 8%, p<0.05). 
the number of partners in the last six months reported was more than 10 for 21% of MSM 
visiting the StI centre (NA Amsterdam), whereas this was only 7% and 5% for heterosexual 
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men and women. However, the MSM with more than 10 partners reported were hardly 
at higher risk of a diagnosed StI (21%) than those with fewer partners (19%). 
young people5.2 
In the young (heterosexual) population, chlamydia remains by far the most frequently 
diagnosed bacterial StI. Girls under 20 years of age are disproportionately affected by 
chlamydia. Heterosexual boys under 20 years and men from 20 to 25 years are both 
at equally high risk for chlamydia. In the StI centres, about 40% of clinic attendees in 
2007 was under 25 years old, i.e. 28% of male and 53% of female consultations; 56% of all 
chlamydia infections was found in this group, 36% of diagnoses in men and 70% of those 
in women. Especially high chlamydia positivity rates are found in young people from 
Surinamese/Antillean origin. young men and young Surinamese/Antillean might need to 
be addressed more specifically in order to motivate them to be tested as well. 
For gonorrhoea, 32% of infections were seen in the group under 25 years old; 65% of 
diagnosis in women and 18% in men. While gonorrhoea and syphilis are in particularly 
diagnosed in older age groups, especially in MSM, the highest gonorrhoea positivity rate 
was seen among heterosexual men, mostly migrants, aged 15-19, suggesting specific 
transmission networks and/or high risk behaviour within this group as well, although 
absolute numbers of infections are low. 
Of the newly reported HIV cases in 2007 in the HIV registry, none were in children below 
15 years. In teenagers between 15-19 years six new HIV cases were reported (0.8% of all); 
two by heterosexual transmission and four in young MSM. young adults (20-24 years) 
accounted for 33 (4%) of all new HIV cases (23 MSM, 10 heterosexuals). 
While the age criterion, i.e. offering free StI-consultation for anyone under 25 years old, 
is highly effective for tracing for chlamydia and gonorrhoea, only a very low number 
of positive tests is found for infectious syphilis and HIV among young people under 25 
years. In the 6,318 young people in this age group (with no other indication of high risk, 
see table A10b), only two cases of infectious syphilis were found and no cases of HIV (of 
6,171 tested for syphilis and 5,987 for HIV, see 32). 
Condom use (at last sexual contact) was reported by 20% of women under 25 years and 
26% of heterosexual men under 25 years (under 20 years: 17% and 26%, respectively). 
Chlamydia was more common among under 25’s who said not to have used condoms 
than those who had, i.e. 15% versus 12% in young women and 16% versus 8% in young 
men. the rate of partner change is higher in young men than young women (14% vs. 
11% with six partners or more in the last six months). Chlamydia positivity rate in young 
people under 25 years was related to the number of partners: 12% in women with one 
partner in the last six months versus 19% in those with six or more partners in this period 
of time, and 11% versus 21% in the same groups of heterosexual men.
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ethnic minority populations5.3 
Compared to the general population in the Netherlands, some ethnic groups were repre-
sented in higher proportion among StI clinic attendees than their proportional presence 
in the country (Surinamese and Netherlands Antillean), others in lower proportion (Moroc-
can and turkish). Migrants from the former Dutch colonies in the Caribbean account for 
27% of the non-western immigrants.49 In 2007, 41% of StI clinic attendees of non-western 
origin had this ethnic background. However, taking into account that the majority of 
consultations take place in ‘urban’ StI centres such as Amsterdam and rotterdam, where 
autochtonous Dutch account for only half of the population, more attendees of ethnic 
origin could have been expected.
As shown in table 5.1, positivity rates for genital chlamydia, gonorrhoea, syphilis and HIV 
remain higher in people from Surinam/ Netherlands Antilles (20%), followed by people 
from Morocco/ North Africa, Asia or Sub Saharan Africa (all 17%). For Dutch attendees, 
StI positivity was 12% (table 5.1). It is not clear if the group visiting the StI centres is 
a subgroup at higher risk than the rest of the Surinamese/Antillean people. However, 
higher positivity rates in this ethnic group have been reported in prevalence surveys as 
well, i.e. for chlamydia 13 and HIV surveys. 50, 51 At present, data from other surveillance 
sources (GP’s, pregnant women) lack information on ethnic group, but these data sources 
will be further investigated in 2008. Apart from the Surinamese/Antillean group, persons 
from North Africa/Morocco and Eastern Europe showed higher positivity rates for gonor-
rhoea and syphilis. Furthermore, the larger part of new HIV cases acquired through 
heterosexual contact did not originate from the Netherlands (77%); most of these (44%) 
were from sub-Saharan Africa. 
the higher StI positivity rates in these ethnic groups, point to the need for more targe-
ted intervention and StI education adjusted to their specific cultural background and 
situation. 
the higher StI/HIV rates in these ethnic groups may be explained by factors such as recent 
migration, contact with people from the home countries or, potentially, different culture/
habits among these ethnic groups. Assortative sexual mixing patterns may contribute to 
high StI prevalence within the ethnic groups. Between 4% and 14% of clinic attendees of 
different non-Dutch ethnic groups, reported sexual contact abroad in the previous three 
months; the country of origin was most frequently reported. Behavioural data in ethnic 
groups showed that the rate of partner change reported was not higher in the ethnic 
groups with higher StI rates mentioned above: people from Europe (other than Eastern 
Europe) had the highest rates, with 34% reporting six or more partners in past six months. 
In autochtonous Dutch clinic attendees this was 11%. Differences in reported condom use 
at most recent sexual contact between autochthonous Dutch and other ethnicities were 
also not significant. Condom use with last partner ranged from 23% (among Moroccans 
and North Africans) to 44% (among Latin and South Americans) per ethnic group. Of the 
different groups, the Latin/South Americans most frequently reported to have had a former 
HIV-test (72%), while this was the least frequently reported by people from turkey (41%). 
the rate of previous positive StI diagnosis was significantly higher among Surinamese 
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and Antillean migrants. Of all Antillean clinic attendees, 19% had a previous positive StI 
diagnosis compared to 9% in Dutch (table 5.1).
Table 5.1: Sexual behaviour among ethnic groups
≥6 
partners**
% 
condom 
use**
% sex 
abroad**
Previous 
HIV-test
Previous 
positive 
HIV-test
Previous 
StI***
StI# 
diagnosis
Netherlands 11.0 26.9 7,8 46.0 1.8 8.5 11.8
turkish 10.9 23,6 7.2 41.4 0,8 7.0 15.3
Moroccan 9.2 23.0 8.2 42.0 0,6 7.7 17.3
Surinamese 3.9 25,2 6.,0 60.5 1.2 9.4 19.4
Antilleans 9.1 25.8 3.8 54.8 2.8 19.1 20.7
East Europeans 14.7 35.9 14.3 61.5 1.1 5.2 15.0
Africans 9.9 31.6 8.0 54.8 1,6 8.2 17.2
Latin 
Americans 13.5 44.1 11.1 71.7 5.3 5.9 14.3
Other 
Europeans* 34.1 32.6 11.9 55.6 1.0 11.9 13.8
Asians 12.2 33.1 8.8 58.9 3.0 8,3 16.8
*  other Europeans=Patients from European countries except Eastern Europe and the Netherlands
**  Amsterdam and utecht not available
*** Amsterdam not available
# At least one of the following: chlamydia, gonorrhoea, syphilis, HIV
 
Injecting drug users5.4 
Injecting drug use accounted for 5% of all registered HIV cases. this proportion has decre-
ased since 1991 to 0.6% of new HIV cases in 2007. In the Amsterdam Cohort Studies, no 
HIV infections were found among non-injecting and injecting hard drug users in 2007. 
these results indicate that IDu currently play a minor role in the current Dutch HIV 
epidemic, however the burden of HIV is high within the group of IDu. 
Of all StI clinic attendees, 0.5% reported to have (ever) injected drugs. Of them, 12% were 
diagnosed with a StI, indicating this group is not at higher StI-risk than others. the 
core group of (injecting) drug users might however not come to the StI centre. Surveil-
lance on infectious diseases to assess prevalence of HIV, HBC, HCV and syphilis through 
specific healthcare services and methadone treatment centres for drug users is set up 
in collaboration with the trimbos Instituut, but data collection from this risk group is 
hampered by limited access.  
CSW and clients5.5 
Persons visiting StI clinics indicating they were working as a CSW or had visited a CSW 
in the past six months did not show a higher infection rate with chlamydia. However, 
positivity rates for gonorrhoea and syphilis were higher in CSW than in women not 
working in commercial sex. twenty percent of gonorrhoea cases and 29% of syphilis cases 
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in women were diagnosed in CSW. Heterosexual men who had reported to have visited 
a CSW recently also had higher gonorrhoea positivity rates than heterosexual men not 
reporting CSW visits. Among men, 5% of the chlamydial infections, 5% of gonorrhoea 
and 2% of infectious syphilis were diagnosed in men who had recent contact with CSW. 
Overall StI positivity was 10% for CSW and 9% for male clients of CSW. 
the majority of CSW reported a previous HIV test (73%) and 31% of clients of CSW had 
had a former HIV-test; 0.2% of CSW and 2.6% of clients of CSW had a previous positive 
HIV-test. Fourteen percent of CSW and 11% of clients of CSW reported a previous positive 
StI diagnosis, which was higher than attendees without recent experience with commer-
cial sex. In spite of lower positivity rates, monitoring of StI and HIV trends in CSW is 
important and providing free testing and care is essential to ensure this high-risk group 
will continue to come to the StI centres.
the median number of sexual contacts reported in the previous six months among CSW 
was 15 (mean=79); the number of partners reported was 3 among male clients of CSW. 
Fourty six percent of CSW and 32% of male clients of CSW reported to have used condoms 
at their last sexual encounter. Five percent of CSW and 11% of clients of CSW had sexual 
contact abroad in the last three months. Most reported countries of clients of CSW were 
thailand, Germany and Brazil. 
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geNeRaL CONCLuSIONS aNd ReCOmmeNdatIONS6 
the national network of StI centres provides StI care for high risk groups. the absolute 
number of new StI consultations seen in the centres has increased steadily every year 
over the last decade. Nevertheless, positivity rates remained stable at an overall of 13%, 
suggesting a consistent successful targeting of those with transmissible StIs. Preliminary 
data from GP surveillance suggest that the increase in StI consultations with stable rates 
of diagnoses occurred not only in the StI centres, but also in the general practice. this 
would indicate that awareness for HIV/StI is rising in the country and more infected 
persons report for care. From a less optimistic point of view, however, it could also indicate 
a failure to bring down StI incidence and transmission rates despite improved access to 
testing and treatment and investments in prevention and health education.  
Homosexual transmission accounted for the majority of new HIV-infections in 2007. 
MSM, and in particular the HIV-positive among them, remain the group most at risk for 
StI in 2007. the re-emergence of LGV, increased reporting of sexually transmitted HCV11 
52, 53 and high numbers of concurrent StI diagnosed in this group, indicate that unsafe 
sex practices are still common among (HIV-positive) MSM. this suggests that prevention 
efforts aimed at this group need to be revisited urgently. Further involvement of HIV 
consultants in StI prevention and control could be explored. Moreover, this also indi-
cates a need to implement routine StI screening (and surveillance) among HIV positive 
MSM. HIV positive patients currently in care are incidentally screened serologically on 
syphilis, HBV and HCV, but no systematic comprehensive clinical screening is in place 
yet. Integrated analysis of StI screening data of all HIV positives may improve insights 
in the prevalence and risks of concurrent infections in HIV positives. 
A major concern remains the ongoing high positivity rate of chlamydia. the main 
burden of chlamydia, the most commonly diagnosed bacterial StI, is carried by young 
heterosexuals. young men seem to be less well reached by the StI centres than young 
women; whether this is an effect of starting sexual experience later than girls or being 
less aware of the usefulness of StI-testing is not known. Alternatively, men might have 
symptomatic chlamydia infections more often and therefore rather visit their GP than an 
StI center. In addition to higher chlamydia risk in young people, chlamydia and other 
bacterial StI appear to be more prevalent in specific ethnic groups. Both risk groups 
are targeted by StI centres; for most StIs, positivity rates appear to stabilize now. the 
large-scale Chlamydia Screening, which has started in 2008 in Amsterdam, rotterdam 
and eastern Zuid-Limburg is directed at all inhabitants from 16 to 29 years old and thus 
aims to bring down chlamydia incidence among the young heterosexual population. 
Extra efforts are made within this program, in the large cities, to motivate specific ethnic 
groups to participate as well.   
the StI trends presented in this report are based on the population seen in the StI centres. 
the StI care provided by these centres is aimed at high quality specialised care with easy 
access for high-risk groups. During 2007, specific quality indicators have been defined 
by a multidisciplinary taskforce54, and following consultations with several stakeholders, 
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these have been endorsed by the Centre for Infectious Disease Control to act as quality 
control framework. At present, more than 95% of StI clinic attendees fulfil one or more 
of the criteria set as indicators of high risk or are tested for reasons of anonymity. the 
current triage through high-risk indicators and routine testing for chlamydia, gonorrhoea 
and syphilis in all clients and HIV and hepatitis B in specific groups will be evaluated in 
2008. HIV testing may be implemented in an ‘opting-out’ system in more StI centres, but 
whether this needs to apply for all clients is still to be decided. During 2008 further evalu-
ation of the effectiveness of the current policy 55 is planned. Visitations to StI centres are 
scheduled, to enable monitoring and evaluation of quality of care at the StI centres. 
Next to the StI/HIV surveillance in StI centers and HIV monitoring through HIV centers, 
other sources of information will be useful to get information on the population outside 
the high-risk groups. GPs are a major provider of StI care to the general population 
(estimated two third of care14). Data from surveillance of GPs (LINH, NIVEL) are now 
analyzed to get estimates of the number of StI-related consultations done by GPs and 
of the prevalence and incidence of the main StIs. More detailed information of testing 
and diagnosis by GPs are already available for men with urethritis-syndrome (2004-2007, 
to be published elsewhere) and will become available from the GP sentinel surveillance 
(huisartsen peilstations NIVEL) by the end of 2008.
Continuous surveillance of behavioural data is important to provide background data to 
observe trends in StI. the results of the behavioural surveillance in 2007 will be published 
elsewhere. the behavioural indicators in the StI surveillance system may be modified 
based on analysis and expert opinions and linked to other, international indicators. 
Migration and travelling play an important role in the occurrence of StI and awareness 
of international trends will be essential to put Dutch behavioural data into perspective 
of future risks. 
GENErAL CONCLuSIONS AND rECOMMENDAtIONS
81
Recommendations6.1 
Strengthening surveillance of STI and HIV:
Strengthen integrated analysis of surveillance data from StI centres with StI data  −
from other sources, such as antenatal data, data from HIV treatment centres and 
GP surveillance networks. 
Link surveillance of  public sexual healthcare (aanvullende seksualiteits hulpverle- −
ning) with StI surveillance (aanvullende curatieve soazorg) to improve integrated 
assessment of StI prevention and cure.
Explore using StI surveillance data to understand different transmission networks  −
of (drug-resistant) StIs in high risk groups such as ethnic minorities, MSM and HIV 
positives.
Monitor closely the high risk group of HIV-positive MSM and potential transmission  −
routes from this group into other groups.
Improve data collection to determine whether diagnosed HIV infections were  −
acquired recently.
Harmonise multidisciplinary guidelines for diagnosis and treatment.  −
Assess and improve strategies to reduce STI transmission:
Evaluate the effectiveness of the current triage and testing policy in the StI centres  −
in reaching high risk groups and reducing StI transmission.
Improve insight in HIV-testing behaviour, including other venues than StI centres,  −
to adjust strategies motivating people to get to know their HIV-status. 
Improve understanding of the impact of StI/HIV co-infections and StI infections  −
at multiple locations on transmission, diagnosis and treatment.
Assess the impact of partner notification on StI/HIV transmission.  −
Assess the impact of chlamydia screening on attendance and StI detection rates  −
in StI centres.
use modelling in estimating StI/HIV transmission based on various data sources.  −
Strengthening molecular typing, for instance for gonorrhoea and HBV. −
Promote (operational) research to identify optimal strategies to interrupt transmis- −
sion among high risk groups.
Set an agenda of research linked to updating guidelines. −
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appeNdIx a      
tabLeS aNd FIguReS StI SuRVeILLaNCe
Table A.1: Number of consultations by sex
Sex total (%)
Men 39824(51.0)
Women
transsexuals*
unknown
38210(48.9)
28(0.0)
1 (0.0)
total 78062
* transsexuals are disregarded in the rest of the tables
Table A.2: Number of consultations per month
Month total (%)
January
February
March
April
May
June
July
August
September
October
November
December
6643(8.5)
5992(7.7)
6642(8.5)
5689(7.3)
6125(7.8)
6661(8.5)
6759(8.7)
7339(9.4)
6425(8.2)
7178(9.2)
6925(8.9)
5655(7.2)
total 78033
Table A.3: Number of consultations by sex and age
Age (years) Men (%) Women (%) total (%)
≤14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
>55
18(0.0)
1572(3.9)
9448(23.7)
8397(21.1)
5630(14.1)
4847(12.2)
3862(9.8)
2673(6.7)
1531(3.8)
1846(4.6)
58(0.2)
4910(12.9)
15756(41.2)
8289(21.7)
3400(8.9)
2270(5.9)
1534(4.0)
1110 (2.9)
560(1.5)
322(0.8)
76(0.1)
6482(8.3)
25204(32.3)
16686(21.4)
9030(11.6)
7117(9.1)
5396(6.9)
3783(4.8)
2091(2.7)
2168(2.8)
total 39824 38209 78033
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Table A.4: Number of consultations by sex and ethnicity 
Ethnicity Men (%) Women (%) total (%)
the Netherlands
turkey
Northern Africa/ Morocco
Surinam
the Netherlands Antilles
Eastern Europe
Sub-Saharan Africa
Latin America
Europe else
Asia
unknown
Else
31487(79.1)
513(1.3)
674(1.7)
1889(4.7)
737(1.9)
417(1.0)
770(1.9)
565(1.4)
671(1.7)
712(1.8)
92(0.2)
1297(3.3)
31101(81.4)
127(0.3)
236(0.6)
1587(4.2)
511(1.3)
975(2.6)
563(1.5)
610(1.6)
1116 (2.9)
583(1.5)
86(0.2)
714(1.9)
62588(80.2)
640(0.8)
910(1.2)
3476(4.5)
1248(1.6)
1392(1.8)
1333(1.7)
1175(1.5)
1787(2.3)
1295(1.7)
178(0.2)
2011(2.6)
total 39824 38209 78033
Table A.5: Number of consultations for men by sexual preference
Sexual preference total (%)
Heterosexual
Homo/bisexual
unknown
28689(72.0)
11048(27.7)
85(0.2)
total 39822
Table A.6: Number of consultations by client of CSW (M) or CSW (F)
Sex worker (or client) Male client (%) Female CSW (%)
No
yes, in past 6 months
unknown
36284(91.1)
3113(7.8)
425(1.1)
34475(90.2)
3395(8.9)
339(0.9)
total 39822 38209
Table A.7: Number of consultations by sex and injecting drug use
Injecting drug use Men (%) Women (%) total (%)
No
yes, ever
yes, in past 6 months
unknown
38261(96.1)
102(0.3)
69(0.2)
1390(3.5)
36444(95.4)
96(0.3)
64(0.2)
1605(4.2)
74705(95.7)
198(0.3)
133(0.2)
2995(3.8)
total 39822 38209 78031
APPENDIx A
87
Table A.8: Number of consultations by sex and prior HIV test 
Prior HIV test Men (%) Women (%) total (%)
No
yes, positive
yes, negative
yes, result unknown
unknown
18610(46.7)
1441(3.6)
18952(47.6)
166(0.4)
653(1.6)
20222(52.9)
29(0.1)
17064(44.7)
143(0.4)
751(2.0)
38832(49.8)
1470(1.9)
36016(46.2)
309(0.4)
1404(1.8)
total 39822 38209 78031
Table A.9: Number of consultations by sex and previous GO/CT/Lues in anamnesis (GGD Amster-
dam is missing)
Previous GO/Ct/Lues Men (%) Women (%) total (%)
yes
No
Do not know
unknown
3353(13.2)
21015(82.8)
246(1.0)
752(3.0)
3254(12.3)
22260(84.1)
204(0.8)
747(2.8)
6607(12.7)
43275(83.5)
450(0.9)
1499(2.9)
total 25366 26465 51831
Table A.10a Reported reasons for consultation (only from January till June, Amsterdam is 
missing)
reason Men (%) Women (%) total (%)
Symptoms 3284(28.1) 3244(26.6) 6528(27.3)
New relationship 2373(20.3) 2588(21.2) 4961(20.8)
risk behaviour 5273(45.2) 5097(41.7) 10370(43.4)
risk behaviour partner 552(4.7) 1236(10.1) 1788(7.5)
Partner HIV positive 45(0.4) 9(0.1) 54(0.2)
Notification 1212(10.4) 831(6.8) 2043(8.6)
Periodic screening 1121(9.6) 1490(12.2) 2611(10.9)
HBV vaccination 464(4.0) 405(3.3) 869(3.6)
Only information 10(0.1) 4(0.0) 14(0.1)
Other 245(2.1) 193(1.6) 438(1.8)
HIV test 827(7.1) 701(5.7) 1528(6.4)
uncertainty, anxi-
ety, concern
2288(19.6) 2695(22.1) 4983(20.9)
Condom failure 354(3.0) 478(3.9) 832(3.5)
Sexual violence 14(0.1) 137(1.1) 151(0.6)
Non HIV declaration or visa 49(0.4) 9(0.1) 58(0.2)
Child wish or pregnancy 114(1.0) 148(1.2) 262(1.1)
Needle stick or bite incident 6(0.1) 11(0.1) 17(0.1)
total consultations 11678 12209 23887
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Table A.10b Reported indication (only from July till December)
Indication Men (%) Women  (%) total  (%)
MSM 5743 (28.0) 0 (0.0) 5743 (14.3)
< 25 years old 5844 (28.5) 10790 (54.6) 16634 (41.3)
CSW 219 (1.1) 1713 (8.7) 1938 (4.8)
Client of CSW 1880 (9.2) 45 (0.2) 1925 (4.8)
StI/HIV endemic area of origin 3225 (15.7) 2730 (13.8) 5966 (14.8)
total consultations 
(with Amsterdam)
20513 19768 40300
Symptoms* 2853 (22.0) 3045 (22.4) 5898 (22.2)
Partner in riskgroup* 4301 (33.2) 2988 (22.0) 7297 (27.5)
referred* 202 (1.6) 188 (1.4) 390 (1.5)
≥ 3 partners in last 6 months* 6601 (51.0) 5342 (39.3) 11944 (45.0)
Notified* 1655 (12.8) 1234 (9.1) 2889 (10.9)
Anonymous test* 6738 (52.0) 6924 (51.0) 13670 (51.5)
Swinger* 676 (5.2) 690 (5.1) 1369 (5.2)
Other* 499 (3.9) 709 (5.2) 1209 (4.6)
total consultations 
(without Amsterdam)
12946  13586  26545  
*=data Amsterdam unavailable
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Table A.11a: Number of diagnoses by sex
Diagnosis Men (%) Women (%) total (%)
Gonorrhoea 1404(13.7) 423(4.9) 1827(9.6)
Chlamydia 3908(38.1) 3893(44.7) 7801(41.1)
Syphilis: primary 189(1.8) 12(0.1) 201(1.1)
“” : secondary 166(1.6) 9(0.1) 175(0.9)
“” : latens recens 162(1.6) 21(0.2) 183(1.0)
“” : latens tarda 45(0.4) 13(0.1) 58(0.3)
“” : not specified 26(0.3) 9(0.1) 35(0.2)
HIV + 262(2.6) 44(0.5) 306(1.6)
Genital warts 1233(12.0) 828(9.5) 2061(10.9)
Genital herpes: prim.: HSV type 1 126(1.2) 149(1.7) 275(1.5)
“” : prim.: HSV type 2 191(1.9) 144(1.7) 335(1.8)
“” : prim.: HSV type unknown 17(0.2) 22(0.3) 39(0.2)
“” : recurrent 16(0.2) 11(0.1) 27(0.1)
Hepatitis B: acute 11(0.1) 10(0.1) 21(0.1)
Hepatitis B: chronic 164(1.6) 59(0.7) 223 (1.2)
Hepatitis B: recovered 1305(12.7) 608(7.0) 1913(10.1)
Non specified uretritis 258(2.5) 26(0.3) 284(1.5)
Candidiasis 230(2.2) 1084(12.4) 1314(6.9)
Bacterial Vaginosis/gardnerella 3(0.0) 1150(13.2) 1153(6.1)
trichomoniasis 8(0.1) 133(1.5) 141(0.7)
Scabies 40(0.4) 1(0.0) 41(0.2)
Pubic Lice 9(0.1) 0(0.0) 9(0.0)
ulcus e.c.i. 169(1.6) 55(0.6) 224(1.2)
Lymphogranuloma venereum 69(0.7) 0(0.0) 69(0.4)
Proctitis 240(2.3) 5(0.6) 245(1.3)
total 10251 (100.0) 8709(100.0) 18960(100.0)
Table A.11b: Location of chlamydial infection by sex and sexual preference
Location Men hetero (%) MSM (%) Women (%) total (%)
urethral/cervical
Anorectal
Oral
unknown
2807(99.6)
0(0.0)
10(0.4)
1(0.0)
455(37.7)
710(58.9)
35(2.9)
6(0.5)
3757(89.2)
306(7.3)
139(3.3)
11(0.3)
7019(85.2)
1016912.3)
184(2.2)
28(0.2)
total 2818(100.0) 1206(100.0) 4213(100.0) 8237(100.0)
Table A.11c: Location of gonorrhoea by sex and sexual preference
Location Men hetero (%) MSM (%) Women (%) total (%)
urethral/cervical
Anorectal
Oral
unknown
429(97.9)
0(0.0)
7(1.6)
2(0.5)
430(36.0)
554(46.4)
209(17.5)
0(0.0)
358(66.8)
88(16.4)
90(16.8)
0(0.0)
1217(56.2)
642(29.6)
306(14.1)
2(0.1)
total 438(100.0) 1193(100.0) 536(100.0) 2058(100.0)
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Table A.14: Diagnoses by sexual preference, men
Diagnosis Heterosexual (%) MSM (%) unknown (%) total 
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
435(31.0)
2811(72.0)
53(10.3)
25(9.6)
832(67.5)
219(63.1)
964(68.8)
1093(28.0)
463(89.6)
235(90.4)
398(32.3)
127(36.6)
3(0.2)
2(0.1)
1(0.1)
0(0.0)
3(0.2)
1(0.3)
1404
3908
517
262
1233
347
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.15a: Diagnoses by client of CSW, men
Diagnosis No yes, in past 
6 months
unknown total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
1324(94.4)
3678(94.2)
499(96.5)
252(96.9)
1156(93.8)
325(93.7)
66(4.7)
187(4.8)
11(2.1)
5(1.9)
65(5.3)
22(6.3)
12(0.9)
41(1.0)
7(1.4)
3(1.2)
12(1.0)
0(0.0)
1404
3908
517
262
1233
347
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.15b: Diagnoses by CSW, women
Diagnosis No yes, in past 
6 months
unknown total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
337(79.7)
3617(92.9)
30(71.4)
37(84.1)
766(92.5)
304(93.8)
84(19.9)
246(6.3)
12(28.6)
7(15.9)
57(6.9)
18(5.6)
2(0.5)
30(0.8)
0(0.0)
0(0.0)
5(0.6)
2(0.6)
423
3893
42
44
828
324
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.16: Diagnoses by injecting drug use
Diagnosis No yes, ever yes, in past 
6 months
unknown total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
1760(96.4)
7512(96.3)
531(95.0)
289(95.1)
1950(94.6)
652(97.2)
2(0.1)
13(0.2)
1(0.2)
1(0.3)
3(0.1)
0(0.0)
1(0.1)
14(0.2)
2(0.4)
2(0.7)
1(0.0)
0(0.0)
62(3.4)
260(3.3)
25(4.5)
12(3.9)
107(5.2)
19(2.8)
1825
7799
559
304
2061
671
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
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Table A.17: Diagnoses by previous HIV test 
Diagnosis No yes, 
positive
yes, 
negative
yes, result 
unknown
unknown total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
557(30.5)
4250(54.5)
115(20.6)
101(33.2)
875(42.5)
258(38.5)
263(14.4)
260(3.3)
173(30.9)
0(0.0)
81(3.9)
60(8.9)
963(52.8)
3133(40.2)
255(45.6)
188(61.8)
1057(51.3)
332(49.5)
15(0.8)
31(0.4)
6(1.1)
6(2.0)
12(0.6)
8(1.2)
27(1.5)
125(1.6)
10(1.8)
9(3.0)
36(1.7)
13(1.9)
1825
7799
559
304
2061
671
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.18a: Diagnoses by previous GO/CT/Lues in anamnesis, men (GGD Amsterdam is missing)
Diagnosis yes No Don’t know unknown total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
258(36.0)
434(17.4)
101(34.0)
49(38.6)
98(14.5)
27(20.8)
439(61.3)
1952(78.5)
191(64.3)
70(55.1)
554(82.0)
97(74.6)
4(0.6)
23(0.9)
2(0.7)
2(1.6)
4(0.6)
1(0.8)
15(2.1)
79(3.2)
3(1.0)
6(4.7)
20(3.0)
5(0.8)
716
2488
297
127
676
130
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.18b: Diagnoses by previous GO/CT/Lues in anamnesis, women (GGD Amsterdam is 
missing)
Diagnosis yes No Don’t know unknown total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
66(24.5)
377(13.4)
3(10.0)
2(13.3)
82(14.9)
15(10.1)
193(71.7)
2340(83.4)
25(83.3)
13(86.7)
453(82.1)
131(87.9)
1(0.4)
19(0.7)
0(0.0)
0(0.0)
0(0.0)
1(0.7)
9(3.3)
70(2.5)
2(6.7)
0(0.0)
17(3.1)
2(1.3)
269
2806
30
15
552
149
* Infectious syphilis includes Lues I, Lues II and Lues latens recens 
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Table A.19a: Number of tests and percentage of positive tests by age, heterosexual men
Age (years) HIV Gonorrhoea Chlamydia Infectious syphilis*
tests % pos. tests % pos. tests % pos. tests % pos.
0-14 8 0 12 0 12 0 12 0
15-19 995 0 1239 2.3 1241 13.9 1232 0
20-24 7063 0 8166 1.5 8164 13.5 8119 0
25-29 6033 0.1 6758 1.5 6762 11.0 6717 0.1
30-34 3615 0.1 3997 1.4 3995 8.3 3961 0.4
35-39 2632 0.2 3003 1.6 3005 6.6 2970 0.2
40-44 1752 0.3 2043 1.4 2043 6.0 2023 0.2
45-49 1195 0 1384 1.5 1384 5.3 1371 0.5
50-54 688 0.1 803 1.9 803 4.4 797 0.6
55 > 764 0.3 910 1.3 908 3.5 902 1.0
total 24746 0.1 28315 1.5 28317 9.9 28104 0.2
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.19b: Number of tests and percentage of positive tests by age, MSM
Age (years) HIV Gonorrhoea Chlamydia Infectious syphilis*
tests % pos. tests % pos. tests % pos. tests % pos.
0-14 3 0 3 0 3 0 3 0
15-19 292 1.4 297 5.4 297 7.4 310 1.0
20-24 1104 2.1 1167 7.2 1165 9.3 1181 2.0
25-29 1318 3.1 1511 11.1 1511 10.1 1515 3.3
30-34 1213 2.5 1524 10.5 1524 12.4 1529 4.3
35-39 1266 4.1 1725 11.0 1723 11.1 1729 5.1
40-44 1192 2.8 1743 9.1 1744 10.1 1743 5.0
45-49 807 3.1 1226 7.4 1227 10.1 1224 5.9
50-54 498 2.6 692 8.1 694 9.2 693 5.9
55 > 688 2.0 897 4.7 895 7.2 892 3.5
total 8381 2.8 10785 8.9 10783 10.1 10819 4.3
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.19c: Number of tests and percentage of positive tests by age, women
Age (years) HIV Gonorrhoea Chlamydia Infectious syphilis*
tests % pos. tests % pos. tests % pos. tests % pos.
0-14 36 0 53 5.7 53 9.4 51 0
15-19 3866 0.0 4853 1.9 4861 16.6 4791 0
20-24 13462 0.1 15633 1.2 15672 12.2 15532 0
25-29 7257 0.1 8193 0.8 8213 8.6 8116 0.1
30-34 3035 0.3 3352 0.9 3352 5.5 3322 0.3
35-39 1992 0.4 2239 1.0 2242 5.1 2216 0.1
40-44 1340 0.3 1510 0.6 1509 3.7 1479 0.5
45-49 979 0.3 1084 1.0 1083 5.1 1070 0.1
50-54 493 0.0 545 0.9 546 5.3 543 0.6
>55 280 0.4 314 0.3 314 6.1 311 1.0
total 32740 0.1 37776 1.1 37845 10.3 37431 0.1
 * Infectious syphilis includes Lues I, Lues II and Lues latens recens
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Table A.20a: Diagnoses in young heterosexual men
Diagnosis 16-17 (%) 18-19 (%) 20-21 (%) 22-24 (%) total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
5(12.2)
35(85.4)
0(0.0)
0(0.0)
0(0.0)
1(2.4)
24(12.8)
134(71.7)
0(0.0)
0(0.0)
26(13.9)
3(1.6)
37(7.2)
397(77.5)
0(0.0)
1(0.2)
59(11.5)
18(3.5)
89(8.9)
706(70.4)
2(0.2)
2(0.2)
173(17.2)
31(3.1)
155
1272
2
3
258
53
total 41 187 512 1003 1743
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.20b: Diagnoses in young MSM
Diagnosis 16-17 (%) 18-19 (%) 20-21 (%) 22-24 (%) total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
2(22.2)
6(66.7)
0(0.0)
0(0.0)
1(11.1)
0(0.0)
13(30.2)
15(34.9)
3(7.0)
4(9.3)
8(18.6)
0(0.0)
26(30.2)
34(39.5)
8(9.3)
8(9.3)
9(10.5)
1(1.2)
58(29.1)
74(37.2)
16(8.0)
15(7.5)
32(16.1)
4(2.0)
99
129
27
27
50
5
total 9 43 86 199 337
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
Table A.20c: Diagnoses in young women
Diagnosis 16-17 (%) 18-19 (%) 20-21 (%) 22-24 (%) total
Gonorrhoea
Chlamydia
Infectious syphilis*
HIV+
Genital warts
Genital herpes
23(9.0)
194(75.8)
0(0.0)
0(0.0)
28(10.9)
11(4.3)
67(8.7)
596(77.4)
1(0.1)
2(0.3)
77(10.0)
27(3.5)
87(7.4)
872(74.2)
2(0.2)
1(0.1)
160(13.6)
53(4.5)
100(7.0)
1046(72.7)
5(0.3)
6(0.4)
210(14.6)
71(4.9)
277
2708
8
9
475
162
total 256 770 1175 1438 3639
* Infectious syphilis includes Lues I, Lues II and Lues latens recens
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Table A.21a: Ethnicity in young men (<25 years) by STI
Ethnicity Gonorrhoea (%) Chlamydia (%) Genital warts (%) Genital herpes (%)
the Netherlands 119(46.5) 1019(72.4) 237(76.7) 42(72.4)
turkey 9(3.5) 16(1.1) 3(1.0) 0(0.0)
N. Africa/Morocco 17(6.6) 36(2.6) 9(2.9) 0(0.0)
Surinam/Neth. Antilles 69(26.9) 196(13.7) 27(8.8) 9(15.5)
Eastern Europe 11(4.3) 14(1.0) 7(2.3) 0(0.0)
Sub-Saharan Africa 7(2.7) 35(2.5) 6(1.9) 2(3.4)
Latin America 5(2.0) 23(1.6) 5(1.6) 0(0.0)
Europe else 6(2.3) 25(1.8) 2(0.6) 0(0.0)
Asia 6(2.3) 20(1.4) 3(1.0) 2(3.4)
unknown 1(0.4) 3(0.2) 2(0.6) 0(0.0)
Else 6(2.3) 22(1.6) 8(2.6) 3(5.2)
total 256 1409 309 58
Table A.21b: Ethnicity in young women (<25 years) by STI 
Ethnicity Gonorrhoea (%) Chlamydia (%) Genital warts (%) Genital herpes (%)
the Netherlands 160(56.9) 2259(82.7) 406(84.9) 126(77.8)
turkey 2(0.7) 5(0.2) 4(0.8) 1(0.6)
N. Africa/Morocco 3(1.1) 18(0.7) 4(0.8) 1(0.6)
Surinam/Neth. Antilles 60(21.4) 220(8.1) 25(5.3) 18(11.1)
Eastern Europe 17(6.0) 65(2.4) 10(2.1) 10(6.2)
Sub-Saharan Africa 2(0.7) 31(1.1) 3(0.6) 0(0.0)
Latin America 3(1.1) 15(0.5) 4(0.8) 0(0.0)
Europe else 26(9.3) 62(2.3) 6(1.3) 1(0.6)
Asia 3(1.1) 29(1.1) 5(1.0) 1(0.6)
unknown 0(0.0) 6(0.2) 3(0.6) 0(0.0)
Else 5(1.8) 20(0.7) 8(1.7) 4(2.5)
total 281 2730 478 162
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Figure A.1 Positivity rates by gender and sexual preference, national STI surveillance network, 
2004-2007
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appeNdIx  b.        
tabLeS aNd FIguReS HIV aNd aIdS SuRVeILLaNCe
HIV cases (total population)
Table B.1: Number of HIV cases, by region and sex
region        Men (%)      Women (%)            total (%)
Amsterdam
North
East
South
West
4812 (44%)
697 (6%)
871 (8%)
1068 (10%)
3449 (32%)
1019 (33%)
232 (7%)
242 (8%)
403 (13%)
1226 (39%)
5831 (42%)
929 (7%)
1113 (8%)
1471 (10%)
4675 (33%)
total 10897 3122 14019
Table B.2: Number of HIV cases, by sex and transmission risk group
transmission risk group        Men (%)      Women (%)            total (%)
MSM
Heterosexual contact
IDu
Blood (products)
Mother to child
Needle stick injury
Other/NK
7480 (69%)
1937 (18%)
478 (4%)
118 (1%)
83 (1%)
23 (0.2%)
778 (7%)
0 (0%)
2637 (84%)
175 (6%)
63 (2%)
72 (2%)
7 (0.2%)
168 (5%)
7480 (53%)
4574 (33%)
653 (5%)
181 (1%)
155 (1%)
30 (0.2%)
946 (7%)
total 10897 3122 14019
NK: not known  
Table B.3: Number of HIV cases, by sex and region of origin
region  of origin        Men (%)      Women (%)            total (%)
the Netherlands
Western Europe
Central Europe
Eastern Europe
Sub-Saharan Africa
Caribbean
Latin America
North America 
North Africa & Middle East
Australia & New Zealand
Oceania & Pacific
South (East) Asia
NK
7013 (64%)
767 (7%)
162 (1%)
59 (0.5%)
1043 (10%)
349 (3%)
750 (7%)
194 (2%)
139 (1%)
31 (0.3%)
34 (0.3%)
292 (3%)
64 (0.6%)
880 (28%)
166 (5%)
36 (1%)
16 (0.5%)
1399 (45%)
160 (5%)
256 (8%)
8 (0.3%)
32 (1%)
1 (0.03%)
6 (0.2%)
157 (5%)
5 (0.2%)
7893 (56%)
933 (7%)
198 (1%)
75 (0.5%)
2442 (17%)
509 (4%)
1006 (7%)
202 (1%)
171 (1%)
32 (0.2%)
40 (0.3%)
449 (3%)
69 (0.5%)
total 10897 3122 14019
NK: not known  
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Table B.4: Number of HIV cases, by transmission risk group and region of origin
region  of origin MSM (%) Heterosexual 
contact (%)
IDu (%)
the Netherlands 
Western Europe 
Central Europe 
Eastern Europe 
Sub-Saharan Africa 
Caribbean 
Latin America 
North America 
North Africa & Middle East 
Australia & Pacific 
South (East) Asia 
NK 
5476 (73%)
577 (8%)
83 (1%)
35 (0.5%)
98 (1%)
209 (3%)
483 (6%)
173 (2%)
50 (0.7%)
24 (0.3%)
2051 (3%)
42 (0.6%)
1368 (30%)
147 (3%)
74 (2%)
20 (0.4%)
2001 (44%)
250 (5%)
428 (9%)
7 (0.2%)
71 (2%)
2 (0.1%)
189 (4%)
7 (0.2%)
416 (64%)
121 (19%)
13 (2%)
13 (2%)
7 (1%)
11 (2%)
24 (4%)
6 (1%)
19 (3%)
1 (0.2%)
14 (2%)
7 (1%)
total 7480 4574 653
NK: not known 
MSM: men having sex with men; IDu: injecting drug user
Table B.5: Number of HIV cases, by age group and sex
Age group Men (%) Women (%) total (%)
<15 108 (1%) 84 (3%) 192 (1%)
15-19 139 (1%) 219 (7%) 358 (3%)
20-24 762 (7%) 503 (16%) 1265 (9%)
25-29 1587 (15%) 718 (23%) 2305 (16%)
30-39 4391 (40%) 1068 (34%) 5459 (39%)
40-49 2639 (24%) 353 (11%) 2992 (21%)
≥ 50
NK
1269 (12%)
2 (0.02%)
176 (6%)
1 (0.03%)
1445 (10%)
3 (0.02%)
total 10897 3122 14019
NK: not known 
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Table B.10: Number of HIV cases, by region of origin and transmission risk group 
transmission risk 
group
the 
Netherlands
Sub-Saharan 
Africa
Surinam Neth. Antilles/
Aruba
Western 
Europe
MSM 5476 (69%) 98 (4%) 210 (34%) 174 (42%) 577 (62%)
Heterosexual contact 1368 (17%) 2001 (82%) 344 (56%) 196 (48%) 147 (16%)
IDu 416 (5%) 7 (0.3%) 21 (3%) 11 (3%) 121 (13%)
Blood (products) 89 (1%) 54 (2%) 6 (1%) 2 (0.5%) 5 (0.5%)
Mother to child 96 (1%) 43 (2%) 1 (0.2%) 2 (0.5%) 3 (0.3%)
Needle stick injury 21 (0.3%) 4 (0.2%) 0 (0%) 1 (0.3%) 2 (0.2%)
Other/NK 427 (5%) 235 (10%) 36 (6%) 25 (6%) 78 (8%)
total 7893 2442 618 411 933
NK: not known
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Figure B.1: Number of HIV cases, by sub-Saharan African Country, by West-European country, 
and by Latin American/Caribbean country
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HIV cases diagnosed in 2007
Table B.11: Number of HIV cases diagnosed in 2007, by region and sex
region        Men (%)      Women (%)            total (%)
Amsterdam
North
East
South
West
277 (39%)
62 (9%)
60 (8%)
74 (10%)
238 (33%)
59 (39%)
9 (6%)
15 (10%)
12 (8%)
58 (38%)
336 (39%)
71 (8%)
75 (9%)
86 (10%)
296 (34%)
total 711 153 864
Table B.12: Number of HIV cases diagnosed in 2007, by sex and transmission risk group
transmission risk group        Men (%)      Women (%)            total (%)
MSM
Heterosexual contact
IDu
Blood (products)
Mother to child
Needle stick injury
Other/NK
561 (79%)
105 (15%)
4 (0.6%)
1 (0.1%)
0 (0%)
0 (0%)
40 (6%)
0 (0%)
140 (92%)
1 (0.7%)
1 (0.7%)
0 (0%)
0 (0%)
11 (7%)
561 (65%)
245 (28%)
5 (0.6%)
2 (0.2%)
0 (0%)
0 (0%)
51 (6%)
total 711 153 864
NK: not known 
Table B.13: Number of HIV cases diagnosed in 2007, by sex and region of origin
region  of origin        Men (%)      Women (%)       total (%)
the Netherlands
Western Europe
Central Europe
Eastern Europe
Sub-Saharan Africa
Caribbean
Latin America
North America 
North Africa & Middle East
Australia & New Zealand
Oceania & Pacific
South (East) Asia
511 (72%)
34 (5%)
12 (2%)
4 (0.6%)
41 (6%)
21 (3%)
52 (7%)
6 (0.8%)
15 (2%)
0 (0%)
1 (0.1%)
13 (2%)
41 (27%)
4 (3%)
1 (0.7%)
0 (0%)
81 (53%)
2 (1%)
15 (10%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
7 (5%)
           552 (64%)
38 (4%)
1 (0.7%)
6 (0.7%)
133 (15%)
23 (3%)
67 (8%)
6 (0.7%)
15 (2%)
0 (0%)
1 (0.1%)
20 (2%)
total 711 153 864
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Table B.16: Number of HIV cases diagnosed in 2007, by age group and sex
Age group Men (%) Women (%) total (%)
<15 1 (0.1%) 0 (0%) 1 (0.1%)
15-19 4 (0.6%) 3 (2%) 7 (0.8%)
20-24 40 (6%) 20 (13%) 60 (7%)
25-29 78 (11%) 29 (19%) 107 (12%)
30-39 247 (35%) 51 (33%) 298 (34%)
40-49 217 (31%) 36 (24%) 253 (29%)
≥ 50 124 (17%) 14 (9%) 138 (16%)
total 711 153 864
Table B.17: Median age (years) of HIV cases diagnosed in 2007, by region of origin and sex
region of origin Men (age/IQr) Women (age/IQr) total (age/IQr)
the Netherlands
Western Europe
Sub-Saharan Africa
Caribbean
Latin America
South (East) Asia
40.6 (33.7-47.9) 
39.1 (34.2-48.8)
38.6 (28.8-40.8)
38.2 (35.2-45.0)
36.9 (30.9-43.4)
28.8 (27.2-38.7)
40.2 (29.1-50.5) 
41.1 (36.1-47.8)
32.5 (27.7-39.4)
43.9 (28.3-59.5)
33.9 (27.0-44.2)
35.7 (27.8-43.8)
40.5 (33.4-48.2) 
39.8 (34.2-48.8)
33.9 (28.0-39.9)
38.2 (35.2-45.1)
36.2 (30.1-43.8)
32.9 (27.4-40.4)
IQr: interquartile range
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aIdS cases and deaths among HIV patients
Table B.18: Number of AIDS diagnoses and deaths among HIV patients (cumulative, per year)
year AIDS diagnoses 
(Cumulative)
AIDS diagnoses 
(year)
Deaths
(Cumulative)
Deaths
(year)
1983 22 22 6 6
1984 53 31 22 16
1985 118 65 52 30
1986 255 137 115 63
1987 500 245 221 106
1988 825 325 356 135
1989 1216 391 558 202
1990 1635 419 827 269
1991 2085 450 1121 294
1992 2595 510 1533 412
1993 3076 481 1960 427
1994 3570 494 2404 444
1995 4103 533 2843 439
1996 4562 459 3170 327
1997 4899 337 3354 184
1998 5137 238 3492 136
1999 5366 229 3627 137
2000 5616 250 3759 132
2001 5877 261 3887 128
2002 6175 298 4011 124
2003 6466 291 4153 142
2004
2005
2006
2007
6746
7077
7340
7515
280
331
223
263
4296
4436
4545
4661
143
140
109
116
Source Deaths among HIV patients: <2002: Statistics Netherlands, CBS; ≥ 2002: data from HMF 
< 1999: AIDS cases registered by Health Inspectorate, from 1999: data from the HMF
NA = not available
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Table B.19: Number of AIDS patients, by year of AIDS diagnosis and transmission risk group
year of  
diagnosis
MSM Hetero-sexual
contact
IDu Blood (con-
tacts)
Mother to 
child
NK/other total
≤ 87 424 (84%) 26 (5%) 28 (6%) 18 (4%) 3 (0.6%) 1 (0.2%) 500
1988 250 (77%) 18 (6%) 39 (12%) 13 (4%) 2 (0.6%) 3 (0.9%) 325
1989 305 (78%) 33 (8%) 36 (9%) 11 (3%) 1 (0.3%) 5 (1%) 391
1990 318 (76%) 34 (8%) 42 (10%) 17 (4%) 3 (0.7%) 5 (1%) 419
1991 335 (74%) 46 (10%) 43 (10%) 19 (4%) 2 (0.4%) 5 (1%) 450
1992 376 (74%) 51 (10%) 60 (12%) 12 (2%) 2 (0.4%) 9 (2%) 510
1993 317 (66%) 80 (17%) 61 (13%) 8 (2%) 3 (0.6%) 12 (2%) 481
1994 314 (64%) 94 (19%) 65 (13%) 14 (3%) 2 (0.4%) 5 (1%) 494
1995 314 (59%) 116 (22%)  74 (14%) 7 (1%) 9 (2%) 13 (2%) 533
1996 299 (65%) 95 (21%) 50 (11%) 5 (1%) 2 (0.4%) 8 (2%) 459
1997 174 (52%) 104 (31%) 43 (13%) 3 (1%) 2 (0.6%) 11 (3%) 337
1998 116 (49%) 78 (33%) 27 (11%) 1 (0.4%) 3 (1%) 13 (5%) 238
1999 119 (52%) 70 (31%) 10 (4%) 5 (2%) 5 (2%) 20 (9%) 229
2000 102 (41%) 104 (42%) 16 (6%)  4 (2%) 4 (2%) 20 (8%) 250
2001 103 (39%) 107 (41%) 10 (4%) 5 (2%) 6 (2%) 30 (11%) 261
2002 113 (38%) 138 (46%) 8 (3%) 4 (1%) 2 (0.7%) 33 (11%) 298
2003 118 (41%) 110 (38%) 14 (5%) 7 (2%) 6 (2%) 36 (12%) 291
2004 111 (40%) 111 (40%) 8 (3%) 3 (1%) 3 (1%) 44 (16%)  280
2005 143 (43%) 129 (39%) 20 (6%) 4 (1%) 1 (0.3%) 34 (10%) 331
2006 114 (43%) 101 (38%) 11 (4%) 2 (0.8%) 0 (0%) 36 (14%) 264
2007 89 (50%) 67 (37%) 7 (4%) 0 (0%) 0 (0%) 16 (9%) 179
total 4554 1712 672 162 61 359 7515
< 1999: AIDS cases registered by Health Inspectorate, from 1999 to 2007: data from the HMF
 
Table B.20: Median age (years) of AIDS patients at AIDS diagnosis, by region of origin and sex
region of origin    Men (age/IQr)  Women (age/IQr)  total (age/IQr)
the Netherlands
Western Europe
Sub-Saharan Africa
Caribbean
Latin America
South (East) Asia
41.2 (35.2-48.5) 
38.6 (32.9-45.0)
34.2 (28.5-39.1)
37.0 (32.4-44.0)
37.4 (32.7-42.8)
39.1 (32.4-46.5)
36.2 (30.0-44.5) 
35.0 (31.4-40.1)
31.7 (26.4-36.3)
38.1 (32.1-44.4)
34.3 (29.0-43.3)
33.1 (28.4-37.4)
40.8 (34.6-48.2) 
38.0 (32.7-44.6)
32.8 (27.4-38.2)
37.5 (32.3-44.1)
37.1 (32.0-42.9)
35.8 (31.2-43.6)
IQr: interquartile range
Table B.21: Number of deaths among HIV/AIDS patients, by sex
Men (%) Women (%) total
2002 104 (84%) 20 (16%) 124
2003 116 (82%) 26 (18%) 142
2004 124 (87%) 19 (13%) 143
2005 119 (85%) 21 (15%) 140
2006 90 (83%) 19 (17%) 109
2007 95 (82%) 21 (18%) 116
Source deaths among HIV/AIDS patients: HIV Monitoring foundation
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Table B.22: Number of death among HIV/AIDS patients **, by year of death, age group* and sex
Age group 2003 2004 2005 2006 2007
M F M F M F M F M F
<20=<2 1 
(0.9%)
2
 (8%)
0
 (0%)
0
 (0%)
0
(0%)
0
(0%)
1
(1%)
0
(0%)
0
(0%)
0
(0%)
20-25 =3 0 
(0%)
1 
(4%)
1
 (0.8%)
0
 (0%)
0
(0%)
1
(5%)
1
(1%)
0
(0%)
3
(3%)
1
(5%)
25-30 =4 3 
(3%)
1
 (4%)
6
(5%)
0
 (0%)
1
(1%)
3
(14%)
1
(1%)
0
(0%)
3
(3%)
2
(10%)
30-35 =5 10 
(9%)
1 
(4%)
16
(13%)
3
(16%)
9
(8%)
6
(29%)
3
(3%)
3
(16%)
10
(11%)
0
(0%)
35-40 =6 12 
(10%)
2 
(8%)
13
(10%)
2
(11%)
15
(13%)
1
(5%)
7
(8%)
3
(16%)
13
(14%)
3
(14%)
40-45 =7 11 
(9%)
3
 (12%)
13
(10%)
3
(16%)
18
(15%)
1
(5%)
3
(3%)
2
(11%)
7
(7%)
3
(14%)
45-50=8 8
(7%)
0
(0%)
15
(12%)
0
(0%)
14
(12%)
1
(5%)
9
(10%)
0
(0%)
6
(6%)
3
(14%)
50-55=9
55-60=10
>65=11
NK=99
11
(9%)
9
(8%)
6
(5%)
45
(39%)
2
(8%)
0
(0%)
2
(8%)
12
(46%)
10
(8%)
7
(6%)
2
(2%)
41 
(33%)
2
(11%)
0
(0%)
1
(5%)
8
(42%)
7
(6%)
8
(7%)
6
(5%)
41
(34%)
0
(0%)
0
(0%)
2
(10%)
6
(29%)
8
(9%)
2
(2%)
12
(13%)
43
(48%)
0
(0%)
2
(11%)
0
(0%)
9
(47%)
6
(0%)
3
(3%)
4
(4%)
40
(42%)
0
(0%)
1
(5%)
0
(0%)
8
(38%)
total 116 26 124 19 119 21 90 19 95 21
* age group at time of death, ** includes all causes of deaths
Source: HIV Monitoring Foundation
Table B.23: Number of HIV cases, by transmission risk group and known country of infection
transmission risk group total number Country of infection 
known (%)
Infected in 
the Netherlands (%)
mSm
- Dutch
- Non-Dutch
Heterosexual contact
- Dutch
- Non-Dutch
Idu
- Dutch
- Non-Dutch
blood (products)
- Dutch
- Non-Dutch
7480
5476
1963
4574
1368
3199
653
416
230
211
110
100
5584 (73%)
4338 (79%)
1133 (58%)
3257 (71%)
1095 (80%)
2161 (68%)
537 (82%)
372 (89%)
164 (71%)
198 (94%)
101 (92%)
88 (88%)
4885 (87%)
4183 (96%)
690 (61%)
1426 (44%)
868 (79%)
558 (26%)
460 (86%)
365 (98%)
94 (57%)
96 (48%)
81 (80%)
14 (16%)
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Figure B.2: Median age (at diagnosis) of heterosexual population over time, by geographic region; 
NL= Netherlands, SSA= sub-Saharan Africa, Lat/Car= Latin America and the Caribbean (Source: 
HMF)
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Figure B.3: Median age (at diagnosis) of MSM population over time, by ethnicity (Dutch/
non-Dutch)
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Table B.24: Summary of HIV/AIDS figures
Cumulative number of HIV cases 1 14019
male/female 10897/3122
Route of transmission 1
- MSM
- Heterosexual contact
- Injecting drug use
- Blood (products)
- Needle stick injury
- Mother to child transmission
- Other/ NK
7480 (53%)
4574 (33%)
653 (5%)
181 (1%)
30 (0.2%)
155 (1%)
946 (7%)
Newly diagnosed HIV cases (2007) 1 864
male/female 711/153
Route of transmission
- MSM
- Heterosexual contact
- Injecting drug use
- Blood (products)
- Needle stick injury
- Mother to child transmission
- Other/NK
561 (65%)
245 (28%)
5 (0.6%)
2 (0.2%)
0 (0%)
0 (0%)
51 (6%)
Cumulative number of aIdS cases since epidemic began 2 7515
Newly diagnosed aIdS cases in 2007 263
Cumulative number of deaths from HIV/aIdS since epidemic began 4661
Cumulative number of deaths from HIV/aIdS in 2007 3 116
* age at diagnosis; 1: data source: HMF, 2: data source AIDS cases < 2000: Health Inspectorate, data source 
AIDS cases ≥ 2000: HMF
 3: data source: HMF
Netherlands
sub-Sahara Africa 
NK 
South East Asia 
Australia & NZ 
Caribbean
Central Europe
Eastern Europe
Western Europe
South America
North America
Middle East & North Africa
         
Men Women
Figure B.4: Geographic distribution country of origin of HIV cases, by sex (men: left, women: 
right; source: HMF)
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appeNdIx C.      
NatIONaL SuRVeILLaNCe OF StI CeNtReS
Coordinating STI centres
GGD Amsterdam: J.S.A.Fennema
H. thiesbrummel
GGD Den Haag: P. van Leeuwen
GGD Groningen: F. de Groot
GGD Hart voor Brabant: J.C.A.M. van de Sande
   H. van Kruchten
   M. Overmars
GGD Nijmegen: A. van Daal
   J. van Baars
   C. Vullings
GGD rotterdam: E. van der Veen
   O. de Zwart
   H. Götz
GGD utrecht: M. Langevoort
   C. Schout
   V. Sigurdsson
GGD Zuid Limburg: C.J.P.A. Hoebe
Regional STI centres
Erasmus MC:  W. van der Meijden
GGD Amstelland-de Meerlanden:  M. Siebbeles
GGD Drenthe:  G. reitsema
GGD Eemland:  r. Heman
GGD Eindhoven:  r. Daemen
GGD Flevoland:  H. Fortuin
GGD Fryslan:  A. Strikwerda
GGD Gelre IJssel:  H. Bos
GGD Gooi en Vechtstreek:  r. Stumpel
GGD Hollands-Midden (Gouda):  K. Visser
GGD Hollands-Midden (Leiden):  B. rump
GGD Kennemerland:  E. den Heijer
GGD Kop van Noord-Holland:  r. Hossen
GGD Midden-Nederland:  J. Ludding
GGD Noord en Midden Limburg:  C. Niesen
GGD Noord-Kennemerland:  F.A.N. Slijkerman Megelink
GGD regio Noord Veluwe:  M. Hosseinia
GGD regio twente:  I. Schreurs
GGD rivierenland:  P. Cornelissen
GGD West-Brabant:  H. Driessen
GGD Westfriesland:  A. Olijhoek
GGD IJssel-Vecht:  H. Bruins
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GGD Zaanstreek-Waterland:  P. Degenaar
GGD Zeeland:  F. Jacobs
GGD Zuid-Holland Zuid:  H. van den Kerkhof
GGD Zuid-Hollandse Eilanden:  A. van Heukelum
GGD Zuidoost Brabant:  P. tolsma
Hulpverlening Gelderland Midden:  S. Feenstra
Laboratories
Academisch Ziekenhuis Maastricht:  E. Stobberingh
Albert Schweitzer Ziekenhuis Dordrecht:  Frenay
Alysis zorggroep Arnhem:  C. van Meerendonk
Amphia Ziekenhuis Breda:  P. van Keulen
Atrium Medisch Centrum Heerlen:  J.H.t. Wagenvoort
Canisius Wilhelmina Ziekenhuis Nijmegen:  t. Simons
Centraal Bacteriologisch en Serologisch 
laboratorium Hilversum:  C.P. timmerman
Diagnostisch Centrum Eindhoven:  L. Harms
Erasmus MC rotterdam:  M. Schutte
GGD Amsterdam:  C. Signet
Gelre Ziekenhuizen Apeldoorn:  F.G.C. Heilman
Groene Hart Ziekenhuis Gouda: F.C. van der Geest
Isala klinieken Zwolle:  P. van de Goor
Jeroen Bosch Ziekenhuis ’s Hertogenbosch:  P. Schneeberger
Laboratoria voor de Pathologische Anatomie en 
Medische Microbiologie Velhoven:  A. Jansz
Laboratorium Microbiologie 
twente-Achterhoek Enschede:  J. Spaargaren
Laboratorium voor de Volksgezondheid in 
Friesland Leeuwarden:  J. van Zeijl
Laurentius Ziekenhuis roermond:  F. Stals
Leiden universitair Medisch Centrum:  A.C.M. Kroes
MC Haaglanden Den Haag:  C.J. Jansen
Meander Medisch Centrum Amersfoort:  H. Schreuder
Medisch Centrum Alkmaar:  J. Sloos
ruwaard van Putten Ziekenhuis Spijkenisse:  H. van Ingen
Slingeland Ziekenhuis Doetinchem:  r. Bosboom
Streeklaboratorium Haarlem:  F. Lamie
Streeklaboratorium Haarlem:  D. Veenendaal
Streeklaboratorium van de Volksgezondheid Deventer:  F.W. Sebens
Streeklaboratorium voor de Volksgezondheid Groningen: B.P. Overbeek
Streeklaboratorium Zeeland Goes:  L. Sabbe
universitair Medisch Centrum utrecht:  .V. van Marken
VieCuri Venlo:  t. trienekens
Vlietland Ziekenhuis Schiedam:  B. Moffie
Zaans Medisch Centrum Zaandam:  C. Fijen
Zeeuws-Vlaanderen, Ziekenhuis terneuzen:  W. Westphaal
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appeNdIx d       
HIV mONItORINg FOuNdatION
Within the framework of the HIV Monitoring Foundation, a substantial number of profes-
sionals are participating:
Treating physicians (*Site coordinating physicians)
Dr. W. Bronsveld*, Drs. M.E. Hillebrand-Haverkort,  − Medisch Centrum Alkmaar
Dr. J.M. Prins*, Dr. J. Branger, Dr. J.K.M. Eeftinck-Schattenkerk, Dr. S.E. Geerlings, Dr.  −
M.H. Godfried, Drs. E.D. Kerver, Prof.dr. J.M.A. Lange, Dr. K.D. Lettinga, Dr. J.t.M. 
van der Meer, Dr. F.J.B. Nellen, Drs. D.P. Olszyna, Dr. t. van der Poll, Prof dr. P. reiss, 
Drs. th.A. ruys, Drs. r. Steingrover, Drs. M. van der Valk, Drs. J.N. Vermeulen, Drs. 
S.M.E. Vrouenraets, Dr. M. van Vugt, Dr. F.W.M.N. Wit, Academisch Medisch Centrum 
bij de Universiteit van Amsterdam
Prof. dr. t.W. Kuijpers, Drs. D. Pajkrt, Dr. H.J. Scherpbier,  − Emma Kinderziekenhuis- 
AMC, Amsterdam
Dr. A. van Eeden,  − St. Medisch Centrum Jan van Goyen, Amsterdam
Prof. dr. K. Brinkman*, Drs. G.E.L. van den Berk, Dr. W.L. Blok, Dr. P.H.J. Frissen, Drs.  −
W.E.M. Schouten, Onze Lieve Vrouwe Gasthuis, Amsterdam
Dr. J.W. Mulder*, Dr. E.C.M. van Gorp, Dr. J. Wagenaar,  − Slotervaart Ziekenhuis, 
Amsterdam
Dr. J. Veenstra*, Dr. W.L.E. Vasmel,  − St. Lucas Andreas Ziekenhuis, Amsterdam
Prof. Dr. S.A. Danner*, Dr. M.A. Van Agtmael, DrS. W.F.W. Bierman, Drs. F.A.P. Claes- −
sen, Dr. r.M. Perenboom, Drs. A. rijkeboer, Drs. M.G.A. van Vonderen, VU Medisch 
Centrum, Amsterdam
Dr. C. richter*, Drs. J. van der Berg, Dr. E.H. Gisolf,  − Ziekenhuis Rijnstate, Arnhem
Dr. r. Vriesendorp*, Dr.F.J.F. Jeurissen,  − Medisch Centrum Haaglanden, locatie West-
einde, Den Haag
Dr. r.H. Kauffmann*, Drs. K. Pogány,  − Haga Ziekenhuis, locatie Leyenburg, Den 
Haag
Dr. B. Bravenboer*,  − Catharina Ziekenhuis, Eindhoven
Dr. C.H.H. ten Napel*, Dr. G.J. Kootstra,  − Medisch Spectrum Twente, Enschede
Dr. H.G. Sprenger*, Dr. S. van Assen, Dr. J.t.M. van Leeuwen,  − Universitair Medisch 
Centrum, Groningen.
Dr. r. Doedens, Dr. E.H. Scholvinck,  − Universitair Medisch Centrum, Beatrix kliniek, 
Groningen
Prof. dr. r.W. ten Kate*, Dr. r. Soetekouw,  − Kennemer Gasthuis, Haarlem
Dr. D. van Houte*, Dr. M.B. Polée,  − Medisch Centrum Leeuwarden
Dr. F.P. Kroon*, Prof. dr. P.J. van den Broek, Prof. dr. J.t. van Dissel, Dr. E.F. Schippers,  −
Leids Universitair Medisch Centrum, Leiden
Dr. G. Schreij*, Dr. S. van der Geest, Dr. S. Lowe, Dr. A. Verbon,  − Academisch Zieken-
huis Maastricht
Dr. P.P. Koopmans*, Drs. C. Bleeker, Dr. r. van Crevel, Prof. dr. r. de Groot, Drs. H.J.M.  −
ter Hofstede, Dr. M. Keuter, Dr. A.J.A.M. van der Ven, Universitair Medisch Centrum 
St. Radboud, Nijmegen
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Dr. M.E. van der Ende*, Dr. I.C. Gyssens, Drs. M. van der Feltz, Drs. Mendoca de  −
Melo, Dr. J.L Nouwen, Dr. B.J.A. rijnders, Drs. t.E.M.S. de Vries, Erasmus Medisch 
Centrum, Rotterdam 
Dr. G. Driessen, Dr. M. van der Flier, Dr. N.G. Hartwig,  − Erasmus Medisch Centrum, 
Sophia, Rotterdam
Dr. J.r. Juttman*, Dr. M.E.E. van Kasteren, Dr. C. Van de Heul,  − St. Elisabeth Zieken-
huis, Tilburg
Prof. dr. I.M. Hoepelman*, Dr. M.M.E. Schneider, Prof. dr. M.J.M. Bonten, Prof. dr.  −
J.C.C. Borleffs, Dr. P.M. Ellerbroek, Drs. C.A.J.J. Jaspers, Dr. t. Mudrikova, Universitair 
Medisch Centrum Utrecht
Dr. S.P.M. Geelen, Dr. t.F.W. Wolfs, Dr. t. Faber,  − Wilhelmina Kinderziekenhuis-UMC, 
Utrecht 
Dr. A.A. tanis*,  − Ziekenhuis Walcheren, Vlissingen
Dr. P.H.P. Groeneveld*,  − Isala Klinieken, Zwolle
Dr. J.G. den Hollander*  − Medisch Centrum Rijnmond Zuid, locatie Clara, Rotterdam
Dr. A. J. Duits, Dr. K. Winkel,  − St. Elisabeth Hospitaal/Stichting Rode Kruis Bloedbank, 
Willemstad, Curaçao.
Virologists
Dr. N.K.t. Back, Dr. M.E.G. Bakker, Prof. dr. B. Berkhout, Dr. S. Jurriaans, Dr. H.L.  −
Zaaijer, Academisch Medisch Centrum, Amsterdam
Dr. th. Cuijpers, CLB Sanquin Blood Supply Foundation, Amsterdam  −
Dr. P.J.G.M. rietra, Dr. K.J. roozendaal, Onze Lieve Vrouwe Gasthuis, Amsterdam −
Drs. W. Pauw, Dr. A.P. van Zanten, P.H.M. Smits, Slotervaart Ziekenhuis, Amster- −
dam
Dr. B.M.E. von Blomberg, Dr. P. Savelkoul, Dr. A. Pettersson, Vu Medisch Centrum,  −
Amsterdam
Dr. C.M.A. Swanink, Ziekenhuis rijnstate, Arnhem −
Dr. P.F.H. Franck, Dr. A.S. Lampe, HAGA ziekenhuis, locatie Leyenburg, Den Haag −
C.L. Jansen, Medisch Centrum Haaglanden, locatie Westeinde, Den Haag −
Dr. r. Hendriks, Streeklaboratorium twente, Enschede −
Dr. C.A. Benne, Streeklaboratorium, Groningen −
Dr. D. Veenendaal, Dr. J. Schirm, Streeklaboratorium Volksgezondheid Kennemer- −
land, Haarlem
Dr. H. Storm, Drs. J. Weel, Drs. J.H. van Zeijl, Laboratorium voor de Volksgezond- −
heid in
Friesland, Leeuwarden −
Prof. Dr. A.C.M. Kroes, Dr. H.C.J. Claas, Leids universitair Medisch Centrum,  −
Leiden
Prof. Dr. C.A.M.V.A. Bruggeman, Drs. V.J. Goossens, Academisch Ziekenhuis Maas- −
tricht
Prof. Dr. J.M.D. Galama, Dr. W.J.G. Melchers, Dr. Verduyn-Lunel, universitair Medisch  −
Centrum St. radboud, Nijmegen
Dr. G.J.J. Doornum, Prof. Dr. A.D.M.E. Osterhaus, Dr. M. Schutten, Erasmus Medisch  −
Centrum, rotterdam
Dr. M.G. Niesters, universitair Medisch Centrum Groningen −
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Dr. A.G.M. Buiting, St. Elisabeth Ziekenhuis, tilburg −
Dr. C.A.B. Boucher, Dr. r. Schuurman, Dr. E.Boel, universitair Medisch Centrum  −
utrecht
Drs. M. Wulf, Dr. A.F. Jansz, Catharina Ziekenhuis, Veldhoven −
Pharmacologists
Dr. A. Veldkamp, Medisch Centrum Alkmaar −
Prof. Dr. J.H. Beijnen, Dr. A.D.r. Huitema, Slotervaart Ziekenhuis, Amsterdam −
Dr. D.M. Burger, universitair Medisch Centrum St. radboud, Nijmegen −
Drs. H.J.M. van Kan, Academisch Medisch Centrum (uvA), Amsterdam −
HIV Treatment Centres
Academisch Medisch Centrum (uVA), Meibergdreef 9, 1105 AZ Amsterdam −
Academisch Ziekenhuis Maastricht, P. Debyelaan 25, 6229 Hx Maastricht −
Catharina Ziekenhuis, Postbus 1350, 5602 ZA Eindhoven −
Emmakinderziekenhuis, AMC Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam −
Erasmus Medisch Centrum, Dr. Molewaterplein 40, 3015 GD rotterdam −
HAGA, locatie Leyenburg, Leyweg 275, 2545 CH Den Haag −
Isala Klinieken, locatie Sophia, Dokter van Heesweg 2, 8025 AB Zwolle −
Kennemer Gasthuis, locatie EG, Boerhaavelaan 22, 2000 AK Haarlem −
Leids universitair Medisch Centrum, rijnsburgerweg 10, 2333 AA Leiden −
Medisch Centrum Alkmaar, Wilhelminalaan 12, 1815 JD Alkmaar −
Medisch Centrum Haaglanden, locatie Westeinde, Lijnbaan 32, 2512 VA Den  −
Haag
Medisch Centrum Leeuwarden, locatie Zuid, H. Dunantweg 2, 8934 AD Leeuwar- −
den
Medisch Centrum rijnmond Zuid, locatie Clara, Olympiaweg 350, 3078 Ht rotter- −
dam
Medisch Spectrum twente, Postbus 50, 7500 KA Enschede −
Onze Lieve Vrouwe Gasthuis,  −
Locatie Oosterpark, 1e Oosterparkstraat 179, 1091 HA Amsterdam −
Locatie Prinsengracht, Prinsengracht 769, 1017 JZ Amsterdam −
St. Medisch Centrum Jan van Goyen, Jan van Goyenkade 1, 1075 HN Amsterdam −
Slotervaartziekenhuis, Louwesweg 6, 1066 CE Amsterdam −
Erasmus Medisch Centrum – Sophia, Dr. Molenwaterplein 40, 3015 GD rotter- −
dam
St. Elisabeth Ziekenhuis, Hilvarenbeekseweg 60, 5022 GC tilburg −
St. Lucas Andreas Ziekenhuis, Postbus 9243, 1006 AE Amsterdam −
Streekziekenhuis Walcheren, Koudekerkseweg 88, 4382 EE Vlissingen; −
universitair Medisch Centrum Groningen, Oostersingel 59, 9715 EZ Groningen −
universitair Medisch Centrum Groningen Beatrix Kliniek, Oostersingel 59, 9715  −
EZ Groningen
universitair Medisch Centrum St. radboud, Postbus 9101, 6500 HB Nijmegen −
universitair Medisch Centrum utrecht, Heidelberglaan 100, 3584 Cx utrecht −
Vu Medisch Centrum, De Boelelaan 1117, 1081 HV Amsterdam −
Wilhelmina Kinderziekenhuis utrecht, Postbus 85090, 3508 AB utrecht −
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Ziekenhuis rijnstate, Wagnerlaan 55, 6815 AD Arnhem −
Stichting rode Kruis Bloedbank, Huize Batavia, Pater Euwenweg 36, Willemstad,  −
Curaçao
St. Elisabeth Hospitaal, Breedestraat 193 (O), Willemstad, Curaçao   −
Other institutions involved
CLB, Stichting Sanquin Bloed-voorziening, Plesmanlaan 125, 1066 Cx Amster- −
dam
Laboratorium voor de Volksgezondheid in Friesland, Postbus 21020, 8900 JA Leeu- −
warden
Streeklaboratorium voor de Volksgezondheid voor Groningen en Drenthe, Van  −
Ketwich Verschuurlaan 92, 9821 SW Groningen
Streeklaboratorium Volksgezondheid Kennemerland, Boerhaavelaan 26, 2035 rE  −
Haarlem
Streeklaboratorium twente-Enschede, Burg. Edo Bergsmalaan 1, 7512 AD  −
Enschede
HIV Monitoring Foundation
Governing Board 2006
Drs. M.A.J.M. Bos, treasurer, ZN −
Prof. Dr. r.A. Coutinho, observer, rIVM −
Prof. Dr. S.A. Danner, chairman, NVAB −
Prof. Dr. J. Goudsmit, member, AMC-uvA −
Prof. Dr. L.J. Gunning-Schepers, member, NFu −
Dr. D.J. Hemrika, secretary, NVZ −
Drs. H. Polee, member, Dutch HIV Association −
Drs. M.I. Verstappen, member, GGD  −
Dr. F. de Wolf, director, HMF −
Advisory Board
Prof. Dr. Sir r.M. Anderson, Imperial College, Faculty of Medicine, Dept. Infectious  −
Diseases Epidemiology, London, united Kingdom
Prof. Dr. J.H. Beijnen, Slotervaart Hospital, Dept. of Pharmacology, Amsterdam −
Dr. M.E. van der Ende, Erasmus Medical Centre, rotterdam −
Prof. Dr. r. de Groot, uMC- St. radboud, Dept. Of Internal Medicine, Nijmegen −
Prof. Dr. I.M. Hoepelman, uMC utrecht, utrecht  −
Dr. r.H. Kauffmann, Leyenburg Hospital, Dept.of Internal Medicine, the Hague −
Prof. Dr. A.C.M. Kroes, LuMC, Clinical Virological Laboratory, Leiden −
Dr. F.P. Kroon (vice chairman), LuMC,  Dept. of Internal Medicine, Leiden −
Prof. Dr. J.M.A. Lange (chairman), AMC, Dept. of Internal Medicine, Amsterdam −
Prof. Dr. G. Pantaleo, Hôpital de Beaumont, Dept. of Virology, Lausanne, Switzer- −
land
Dhr. C. rümke, Dutch HIV Association, Amsterdam −
Prof. Dr. P. Speelman, AMC, Dept of Internal Medicine, Amsterdam −
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Working group Clinical Aspects 
Dr. K. Boer, AMC, Dept. of Obstetrics/Gynaecology, Amsterdam −
Prof. Dr. K. Brinkman (vice chairman), OLVG, Location Oosterpark, Dept of Internal  −
Medicine, Amsterdam
Dr. D.M. Burger (subgr. Pharmacology), uMC- St. radboud, Dept. of Clinical Phar- −
macy, Nijmegen
Dr. M.E. van der Ende (chairman), Erasmus Medical Centre, Dept. of Internal Medi- −
cine, rotterdam
Dr. S.P.M. Geelen, uMCu-WKZ, Dept of Paediatrics, utrecht −
Dr. J.r. Juttmann, St. Elisabeth Hospital, Dept. of Internal Medicine, tilburg −
Dr. r.P. Koopmans, uMCN-St. radboud, Dept. of Internal Medicine, Nijmegen −
Prof. Dr. t.W. Kuijpers, AMC, Dept. of Paediatrics, Amsterdam −
Dr. W.M.C. Mulder, Dutch HIV Association, Amsterdam −
Dr. C.H.H. ten Napel, Medisch Spectrum twente, Dept. of Internal Medicine,  −
Enschede
Dr. J.M. Prins, AMC, Dept. of Internal Medicine, Amsterdam −
Prof. Dr. P. reiss (subgroup toxicity), AMC, Dept. of Internal Medicine, Amster- −
dam
Dr. G. Schreij, Academic Hospital, Dept. of Internal Medicine, Maastricht −
Drs. H.G. Sprenger, Academic Hospital, Dept. of Internal Medicine, Groningen −
Working group Virology
Dr. N.K.t. Back, AMC, Dept. of Human retrovirology, Amsterdam −
Dr. C.A.B. Boucher, uMCu, Eykman-Winkler Institute, utrecht −
Dr. H.C.J. Claas, LuMC, Clinical Virological Laboratory, Leiden −
Dr. G.J.J. Doornum, Erasmus Medical Centre, Dept. of Virology, rotterdam −
Prof. Dr. J.M.D. Galama, uMCN- St. radboud, Dept. of Medical Microbiology, Nijme- −
gen
Dr. S. Jurriaans, AMC, Dept. of Human retrovirology, Amsterdam −
Prof. Dr. A.C.M. Kroes (chairman), LuMC, Clinical Virological Laboratory, Leiden −
Dr. W.J.G. Melchers, uMCN St. radboud, Dept. of Medical Microbiology, Nijme- −
gen
Prof. Dr. A.D.M.E. Osterhaus, Erasmus Medical Centre, Dept. of Virology, rotter- −
dam 
Dr. P. Savelkoul, Vu Medical Centre, Dept. of Medical Microbiology, Amsterdam −
Dr. r. Schuurman, uMCu, Dept. of Virology, utrecht −
Dr. A.I. van Sighem, HIV Monitoring Foundation, Amsterdam −
Data collectors
y.M. Bakker, C.r.E. Lodewijk, y.M.C. ruijs-tiggelman, D.P. Veenenberg-Benschop,  −
I. Farida, AMC, Amsterdam
C. Leenders, r. Vergoossens, Academic Hospital Maastricht −
B. Korsten, S. de Munnik, Catharina Hospital Eindhoven −
M. Bendik, C. Kam-van de Berg, A. de Oude, t. royaards, Erasmus Medical Centre,  −
rotterdam
G. van der Hut, Haga Hospital, Location Leyenburg, the Hague −
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A. van den Berg, A.G.W. Hulzen, Isala Klinieken, Zwolle −
P. Zonneveld, Kennemer Gasthuis, Haarlem −
M.J. van Broekhoven-Kruijne, Leids universitair Medisch Centrum, Leiden −
D. Pronk, F.A. van truijen-Oud, Medical Centre Alkmaar −
S. Bilderbeek, Medical Centre Haaglanden, location Westeinde, the Hague −
A. Ballemans, S. rotteveel, Medical Centre Leeuwarden −
J. Smit, J. den Hollander, Medical Centre rijnmond Zuid, rotterdam −
H. Heins, H. Wiggers, Medisch Spectrum twente, Enschede −
B.M. Peeck, E.M. tuyn- de Bruin, OLVG, Amsterdam −
C.H.F. Kuiper, Medical Centre Jan van Goyen, Amsterdam −
E. Oudmaijer-Sanders, Slotervaart Hospital, Amsterdam −
r. Santegoeds, B. van der Ven, St. Elisabeth Hospital, tilburg −
M. Spelbrink, St. Lucas Andreas Hospital, Amsterdam −
M. Meeuwissen, universitair Medisch Centrum St. radboud, Nijmegen −
J. Huizinga, C.I. Nieuwenhout, universitair Medische Centrum Groningen −
M. Peters, C.S.A.M. van rooijen, A.J. Spierenburg, universitair Medisch Centrum  −
utrecht
C.J.H. Veldhuyzen, Vu Medisch Centrum, Amsterdam −
C.W.A.J. Deurloo-van Wanrooy, M. Gerritsen, rijnstate Hospital, Arnhem −
y.M. Bakker, Walcheren Hospital, Vlissingen −
S. Dekker- Meyer, y.M.C. ruijs-tiggelman, St. Elisabeth Hospital/Stichting rode Kruis  −
Bloedbank, Willemstad, Curaçao
Personnel HIV Monitoring Foundation Amsterdam
y.M. Bakker, data collection AMC −
r.F. Beard, registration & patient administration −
Drs. D.O. Bezemer, data analysis −
D. de Boer, financial controlling −
I.H.M. de Boer, assistant-personell −
M.J. van Broekhoven-Kruijne, data collection LuMC −
Drs. D.N. de Gouw, communication manager −
Drs. L.A.J. Gras, data analysis −
Drs. S. Grivell, data monitor   −
L.G.M. de Groot-Berndsen, data collection (from January 15, 2007) −
Drs. M.M. Hillebregt, data monitoring −
Drs. A.M. Kesselring, data analysis  −
Drs. B. Slieker, data monitoring −
C.H.F. Kuiper, data collection St. Medisch Centrum Jan van Goyen −
C.r.E. Lodewijk, data collection AMC −
Drs. H.J.M. van Noort, assistant financial controlling −
B.M. Peeck, data collection OLVG Oosterpark −
y.M.C. ruijs-tiggelman, data collection AMC −
Drs. G.E. Scholte, executive secretary −
Dr. A.I. van Sighem, data analysis −
Drs. B. Slieker, data monitoring −
Dr. Ir. C. Smit, data analysis −
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E.M. tuyn-de Bruin, data collection OLVG Oosterpark −
D.P. Veenenberg-Benschop, data collection AMC −
E. Overheul, assistant data monitor (from July 2007 until October 31, 2007) −
Ing.E.C.M. Verkerk, data monitoring −
C.W.A.J. Deurloo-van Wanrooy, data collection rijnstate −
Dr. F. de Wolf, director −
Drs. S. Zaheri, data quality control −
Drs. Zhang, data analysis  −
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